US624012A
(en)
|
|
1899-05-02 |
|
Stenciling or decorative device |
US568822A
(en)
|
|
1896-10-06 |
|
Lamp-wick and art of producing same |
US482828A
(en)
|
|
1892-09-20 |
|
Locomotive |
AU527784B2
(en)
|
1978-05-26 |
1983-03-24 |
Bang, Hans Olaf Dr. |
Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
|
JPS57112593A
(en)
|
1980-12-26 |
1982-07-13 |
Koken Boring Machine Co |
Lathe drill
|
US4377526A
(en)
|
1981-05-15 |
1983-03-22 |
Nippon Suisan Kaisha, Ltd. |
Method of purifying eicosapentaenoic acid and its esters
|
US4526902A
(en)
|
1983-10-24 |
1985-07-02 |
Century Laboratories, Inc. |
Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
|
CA1239587A
(en)
|
1983-10-24 |
1988-07-26 |
David Rubin |
Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
|
US4822803A
(en)
|
1983-10-31 |
1989-04-18 |
Merck Frosst Canada, Inc. |
Benzofuran 2-carboxylic acid hydrazides useful as inhibitors of leukotriene biosynthesis
|
US4663347A
(en)
|
1983-10-31 |
1987-05-05 |
Merck Frosst Canada, Inc. |
Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
|
US4933351A
(en)
|
1983-10-31 |
1990-06-12 |
Merck Frosst Canada, Inc. |
Benzofuran 2-carbox amides useful as inhibitors of leukoriene biosynthesis
|
US4745127A
(en)
|
1983-10-31 |
1988-05-17 |
Merck Frosst Canada, Inc. |
Benzyl esters of benzofuran-2-carboxylic acids useful as inhibitors of leukotriene biosynthesis
|
US4673684A
(en)
|
1984-04-04 |
1987-06-16 |
Terumo Corporation |
Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
|
JPS6135356A
(ja)
|
1984-07-27 |
1986-02-19 |
Nippon Oil & Fats Co Ltd |
血液脂質脂肪酸の分析方法
|
US4728735A
(en)
|
1984-10-15 |
1988-03-01 |
Merck & Co., Inc. |
10,11-dihydro-dibenzo-[b,f][1,4]-thiazepin derivatives
|
GB8505285D0
(en)
|
1985-03-01 |
1985-04-03 |
Beecham Group Plc |
Compounds
|
US4624964A
(en)
|
1985-03-27 |
1986-11-25 |
E. I. Du Pont De Nemours And Company |
Aryl oxo-alkynoates as 5-lipoxygenase inhibitors
|
ZA863425B
(en)
|
1985-05-08 |
1988-01-27 |
Du Pont |
2-substituted-1-naphthols as 5-lipoxygenase inhibitors
|
US4803279A
(en)
|
1985-05-23 |
1989-02-07 |
Smithkline Beckman Corporation |
1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines.
|
US5008390A
(en)
|
1985-05-23 |
1991-04-16 |
Smithkline Beckman Corporation |
Compounds for preparing 6-phenyl-2,3-dihydroimidazo[2,1-b]-thiazoles and corresponding thiazines
|
US4786755A
(en)
|
1985-06-03 |
1988-11-22 |
Warner-Lambert Company |
Diphenic acid monoamides
|
US4602023A
(en)
|
1985-06-03 |
1986-07-22 |
Warner-Lambert Company |
Diphenic acid monoamides
|
GB8515522D0
(en)
|
1985-06-19 |
1985-07-24 |
Beecham Group Plc |
Compounds
|
EP0347509A1
(en)
|
1988-06-21 |
1989-12-27 |
Century Laboratories Inc. |
A process of extraction and purification of polyunsaturated fatty acids from natural sources
|
US4939169A
(en)
|
1985-09-20 |
1990-07-03 |
The Upjohn Company |
1,4-naphthalenediol and 1,4-hydroquinone derivatives
|
JPS63501288A
(ja)
|
1985-09-20 |
1988-05-19 |
ジ・アップジョン・カンパニ− |
1,4−ナフタレンジオ−ルおよび1,4−ヒドロキノン誘導体
|
JPS6272657A
(ja)
|
1985-09-27 |
1987-04-03 |
Terumo Corp |
アミド誘導体およびこれを含有する5−リポキシゲナ−ゼ作用阻害剤
|
US4694018A
(en)
|
1985-11-29 |
1987-09-15 |
G. D. Serale & Co. |
Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives
|
US5134150A
(en)
|
1985-12-12 |
1992-07-28 |
Smithkline Beecham Corporation |
Inhibition of the 5-lipoxygenase pathway
|
US4686231A
(en)
|
1985-12-12 |
1987-08-11 |
Smithkline Beckman Corporation |
Inhibition of 5-lipoxygenase products
|
US4751310A
(en)
|
1985-12-12 |
1988-06-14 |
Smithkline Beckman Corporation |
Inhibition of the 5-lipoxygenase pathway
|
US4847270A
(en)
|
1985-12-12 |
1989-07-11 |
Smithkline Beckman Corporation |
Inhibition of the 5-lipoxygenase pathway utilizing certain 2,2'-alkyldiyl bis(thio)bis-imidazoles and derivatives
|
US4719218A
(en)
|
1985-12-12 |
1988-01-12 |
Smithkline Beckman Corporation |
Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor
|
US4728656A
(en)
|
1985-12-12 |
1988-03-01 |
Smithkline Beckman Corporation |
2,2-alkyldiylbis(thio)bis(imidazoles) useful for inhibition of the 5-lipoxygenase pathway
|
US4755524A
(en)
|
1986-01-31 |
1988-07-05 |
G. D. Searle & Co. |
Novel phenolic thioethers as inhibitors of 5-lipoxygenase
|
US4711903A
(en)
|
1986-01-31 |
1987-12-08 |
G. D. Searle & Co. |
Phenolic thioethers as inhibitors of 5-lipoxygenase
|
IE59813B1
(en)
|
1986-05-09 |
1994-04-06 |
Warner Lambert Co |
Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
|
US4794114A
(en)
|
1986-08-19 |
1988-12-27 |
Smithkline Beckman Corporation |
Inhibition of interleukin-1 production by monocytes and/or macrophages
|
US4672075A
(en)
|
1986-08-26 |
1987-06-09 |
E. R. Squibb & Sons |
7-Oxabicyclo(2.2.1)heptane hydroxamic acid derivatives useful as antiinflammatory, antiasthma and antipsoriatic agents
|
US4920098A
(en)
|
1986-09-17 |
1990-04-24 |
Baxter International Inc. |
Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
|
US4695585A
(en)
|
1986-09-23 |
1987-09-22 |
E. R. Squibb & Sons, Inc. |
7-oxabicyclo(2.2.1)heptane analogs useful as inhibitors of 5-lipoxygenase and cyclooxygenase
|
US4695586A
(en)
|
1986-09-23 |
1987-09-22 |
E. R. Squibb & Sons, Inc. |
7-oxabicyclo(2.2.1)heptane-based derivatives useful as antiinflammatory, antiasthma and antipsoratic agents
|
CA1321767C
(en)
|
1986-12-26 |
1993-08-31 |
Noriko Okazaki |
Process for production of eicosapentaenoic acid
|
US4861798A
(en)
|
1986-12-29 |
1989-08-29 |
Bristol-Myers Company |
Lipoxygenase inhibitory compounds
|
US4731382A
(en)
|
1986-12-29 |
1988-03-15 |
Bristol-Myers Company |
Lipoxygenase inhibitory phenylalkanohydroxamic acids
|
JPS63185390A
(ja)
|
1987-01-27 |
1988-07-30 |
Suntory Ltd |
藻類によるエイコサペンタエン酸の製造方法
|
US5250565A
(en)
|
1987-02-10 |
1993-10-05 |
Abbott Laboratories |
Indole-,benzofuran-,and benzothiophene-containing lipoxygenase-inhibiting compounds
|
US4877881A
(en)
|
1987-04-06 |
1989-10-31 |
Warner-Lambert Company |
Process of preparing pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors
|
US4889941A
(en)
|
1987-04-23 |
1989-12-26 |
Fisons Corporation |
Synthetic flavonoids as inhibitors of leukotrienes and 5-lipoxygenase
|
US5252333A
(en)
|
1987-04-27 |
1993-10-12 |
Scotia Holdings Plc |
Lithium salt-containing pharmaceutical compositions
|
US5162365A
(en)
|
1987-05-07 |
1992-11-10 |
G. D. Searle & Co. |
5-lipoxygenase inhibitors
|
US5036105A
(en)
|
1987-05-07 |
1991-07-30 |
G. D. Searle & Co. |
5-lipoxygenase inhibitors
|
US4801611A
(en)
|
1987-05-07 |
1989-01-31 |
G. D. Searle & Co. |
5-lipoxygenase inhibitors
|
GB8711802D0
(en)
|
1987-05-19 |
1987-06-24 |
Fujisawa Pharmaceutical Co |
Dithioacetal compounds
|
US4835190A
(en)
|
1987-06-05 |
1989-05-30 |
G. D. Searle & Co. |
Phenolic thioethers as inhbitors of 5-lipoxygenase
|
US4835189A
(en)
|
1987-06-05 |
1989-05-30 |
G. D. Searle & Co. |
Phenolic thioalkylamides as inhibitors of 5-lipoxygenase
|
US5198468A
(en)
|
1987-06-24 |
1993-03-30 |
Efamol Holdings Plc |
Essential fatty acid composition
|
US5086052A
(en)
|
1987-07-17 |
1992-02-04 |
Abbott Laboratories |
Substituted 1,4,5,6-tetrahydro-2H-pyridazin-3-one and -3-thione compounds having lipoxygenase inhibitory activity
|
US4970210A
(en)
|
1987-07-17 |
1990-11-13 |
Abbott Laboratories |
Triazinone lipoxygenase compounds
|
US4843095A
(en)
|
1987-08-07 |
1989-06-27 |
Century Laboratories, Inc. |
Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
|
FR2621038B1
(fr)
|
1987-09-28 |
1989-12-29 |
Rhone Poulenc Sante |
Derives d'alcadienes, leurs preparations, les medicaments les contenant et produits intermediaires
|
DE3888694T2
(de)
|
1987-10-16 |
1994-08-25 |
Terumo Corp |
Isoprenoid-derivate und arzneimittelzubereitung, die diese enthält.
|
US6166031A
(en)
|
1987-10-19 |
2000-12-26 |
Pfizer Inc, |
Substituted tetralins, chromans and related compounds in the treatment of asthma
|
US5059609A
(en)
|
1987-10-19 |
1991-10-22 |
Pfizer Inc. |
Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
|
CA1334975C
(en)
|
1987-11-13 |
1995-03-28 |
James H. Holms |
Furan and pyrrole containing lipoxygenase inhibiting compounds
|
JPH01149764A
(ja)
|
1987-12-07 |
1989-06-12 |
Green Cross Corp:The |
ビス−s−アルキルベンゼン誘導体
|
CA1331757C
(en)
|
1988-02-29 |
1994-08-30 |
Janssen Pharmaceutica Naamloze Vennootschap |
5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
|
US5112868A
(en)
|
1988-05-19 |
1992-05-12 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
|
US4943587A
(en)
|
1988-05-19 |
1990-07-24 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
|
US5665752A
(en)
|
1988-07-26 |
1997-09-09 |
Sankyo Company, Limited |
Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
|
US5354768A
(en)
|
1988-07-26 |
1994-10-11 |
Sankyo Company, Limited |
Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
|
US5232939A
(en)
|
1988-07-26 |
1993-08-03 |
Sankyo Company Limited |
Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
|
US5260294A
(en)
|
1988-08-09 |
1993-11-09 |
Hoffman-La Roche Inc. |
Chromanes and their pharmaceutical compositions and methods
|
GB8819110D0
(en)
|
1988-08-11 |
1988-09-14 |
Norsk Hydro As |
Antihypertensive drug & method for production
|
IE63225B1
(en)
|
1988-09-13 |
1995-04-05 |
Efamol Holdings |
Use of fatty acids in the treatment of myalgic encephalomyelitis
|
GB2223943A
(en)
|
1988-10-21 |
1990-04-25 |
Tillotts Pharma Ag |
Oral disage forms of omega-3 polyunsaturated acids
|
US5066658A
(en)
|
1988-11-10 |
1991-11-19 |
Ortho Pharmaceutical Corporation |
Substituted hydroxyureas
|
US5256680A
(en)
|
1988-11-29 |
1993-10-26 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
|
US5155122A
(en)
|
1988-11-29 |
1992-10-13 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
|
US5068251A
(en)
|
1988-12-16 |
1991-11-26 |
Abbott Laboratories |
Lipoxygenase inhibiting compounds
|
US4935243A
(en)
|
1988-12-19 |
1990-06-19 |
Pharmacaps, Inc. |
Chewable, edible soft gelatin capsule
|
US5234950A
(en)
|
1988-12-23 |
1993-08-10 |
Imperial Chemical Industries Plc |
Tetrahydrofuran derivatives
|
IL92620A0
(en)
|
1988-12-23 |
1990-08-31 |
Ici Pharma |
Cycloalkane derivatives
|
US5217971A
(en)
|
1989-01-05 |
1993-06-08 |
Fujisawa Pharmaceutical Co., Ltd. |
Thiazole compounds and pharmaceutical composition comprising the same
|
US5145860A
(en)
|
1989-01-05 |
1992-09-08 |
Fujisawa Pharmaceutical Co., Ltd. |
Thiazole compounds and pharmaceutical composition comprising the same
|
US5229386A
(en)
|
1989-01-05 |
1993-07-20 |
Fujisawa Pharmaceutical Co., Ltd. |
Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
|
JP2839276B2
(ja)
|
1989-01-23 |
1998-12-16 |
日本分光工業株式会社 |
超臨界流体抽出・分離方法及び装置
|
US5217977A
(en)
|
1989-02-28 |
1993-06-08 |
Imperial Chemical Industries Plc |
Heterocyclic cycloalkanes
|
GB8906369D0
(en)
|
1989-03-20 |
1989-05-04 |
Tisdale Michael J |
Eicosapentaenoic acid
|
US5457130A
(en)
|
1989-03-20 |
1995-10-10 |
Cancer Research Campaign Technology Limited |
Eicosapentaenoic acid used to treat cachexia
|
WO1990012010A1
(en)
|
1989-04-07 |
1990-10-18 |
Pfizer Inc. |
Substituted chromans in the treatment of asthma, arthritis and related diseases
|
US5248685A
(en)
|
1989-04-07 |
1993-09-28 |
Pfizer Inc. |
Substituted 1-[3-(heteroarylmethoxy)phenyl]alkanols and related compounds in the treatment of asthma
|
US5300655A
(en)
|
1989-04-18 |
1994-04-05 |
Pfizer Inc. |
2-carboxy-thiophene derivatives
|
US5047554A
(en)
|
1989-04-18 |
1991-09-10 |
Pfizer Inc. |
3-substituted-2-oxindole derivatives
|
US5006549A
(en)
|
1989-05-24 |
1991-04-09 |
Merck & Co., Inc. |
Novel 7-aroyl-4-hydroxy-3-methyl-benzofurans as dual inhibitors of cyclooxygenase and 5-lipoxygenase
|
US5066668A
(en)
|
1989-06-09 |
1991-11-19 |
Warner-Lambert Co. |
Triazole derivatives of fenamates as antiinflammatory agents
|
US4962119A
(en)
|
1989-06-09 |
1990-10-09 |
Warner-Lambert Company |
Triazole derivatives of fenamates as antiinflammatory agents
|
US5384318A
(en)
|
1989-06-22 |
1995-01-24 |
Pfizer Inc. |
Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
|
DE69009887T2
(de)
|
1989-07-26 |
1994-09-22 |
Ici Pharma |
Bizyklische Derivate.
|
US4975457A
(en)
|
1989-09-25 |
1990-12-04 |
Merck & Co., Inc. |
Trans 2,3-disubstituted-2,3-dihydro-5-hydroxy-benzofurans as inhibitors of leukotriene biosynthesis
|
US4978679A
(en)
|
1989-09-25 |
1990-12-18 |
Merck & Co., Inc. |
6- and/or 7-substituted-1,2,3,4,4A,9B-hexahydro-8-hydroxydibenzofuran-3-ols as inhibitors of leukotriene biosynthesis
|
GB9018134D0
(en)
|
1989-09-29 |
1990-10-03 |
Ici Plc |
Heterocyclic derivatives
|
JPH03148217A
(ja)
|
1989-11-02 |
1991-06-25 |
Terumo Corp |
フエノキシプロピルアミン誘導体またはその塩ならびにこれらを含有する抗潰瘍剤
|
US5504108A
(en)
|
1990-01-12 |
1996-04-02 |
The Ohio State University Research Foundation |
Optically pure 4-aryl-2-hydroxytetronic acids
|
US5093356A
(en)
|
1990-01-16 |
1992-03-03 |
Merck Frosst Canada, Inc. |
Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
|
US5036067A
(en)
|
1990-03-14 |
1991-07-30 |
Merck & Co., Inc. |
Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
|
US5234937A
(en)
|
1990-03-27 |
1993-08-10 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxphenyl oxazolyl methanones and related compounds as antiinflammatory agents
|
US5102897A
(en)
|
1990-03-27 |
1992-04-07 |
Warner-Lambert Company |
3,5-ditertiarybutyl-4-hydroxyphenyl, 1,3,4-thiadiazoles and oxadiazoles linked by carbon, oxygen, and sulfur residues
|
US5086064A
(en)
|
1990-03-27 |
1992-02-04 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl thiazolyl, oxazolyl, and imidazolyl methanones and related compounds as antiinflammatory agents
|
US5143928A
(en)
|
1990-03-27 |
1992-09-01 |
Warner-Lambert Company |
3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
|
US5234939A
(en)
|
1990-03-27 |
1993-08-10 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl imidazolyl methanones and related compounds as antiinflammatory agents
|
DK95490D0
(da)
|
1990-04-18 |
1990-04-18 |
Novo Nordisk As |
Fremgangsmaade til fremstilling af triglycerid og triglyceridsammensaetning
|
HUT65614A
(en)
|
1990-04-30 |
1994-07-28 |
Isis Pharmaceuticals Inc |
Process for the oligonucleotide modulation of arachidonic acid metabolism
|
CA2043615C
(en)
|
1990-06-04 |
2001-08-14 |
Kazuhiko Hata |
Method of producing eicosapentaenoic acid or the ester derivative thereof
|
GB9012651D0
(en)
|
1990-06-06 |
1990-07-25 |
Efamol Holdings |
Essential fatty acid treatment
|
IE911853A1
(en)
|
1990-06-21 |
1992-01-01 |
Ici Plc |
Heterocyclene derivatives
|
US5254581A
(en)
|
1990-06-21 |
1993-10-19 |
Imperial Chemical Industries Plc |
Pyran derivatives and their use as inhibitors of 5-lipoxygenase
|
AU637500B2
(en)
|
1990-06-21 |
1993-05-27 |
Zeneca Limited |
Bicyclic heterocyclic compounds
|
US5064851A
(en)
|
1990-07-24 |
1991-11-12 |
Pfizer Inc. |
3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
|
AU8440991A
(en)
|
1990-09-07 |
1992-03-30 |
G.D. Searle & Co. |
Phenolic thioetheramides as 5-lipoxygenase inhibitors
|
JPH04134077A
(ja)
|
1990-09-21 |
1992-05-07 |
Taiho Yakuhin Kogyo Kk |
イソオキサゾール化合物
|
US5811432A
(en)
|
1990-11-09 |
1998-09-22 |
Pfizer Inc |
Azaoxindole derivatives
|
JP3103588B2
(ja)
|
1990-11-16 |
2000-10-30 |
持田製薬株式会社 |
リポプロテイン(a)低下剤
|
US5177079A
(en)
|
1991-01-31 |
1993-01-05 |
Warner-Lambert Company |
2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
|
US5248682A
(en)
|
1991-01-31 |
1993-09-28 |
Warner-Lambert Company |
2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
|
EP0505122A1
(en)
|
1991-03-21 |
1992-09-23 |
Zeneca Limited |
Alpha, alpha-dialkylbenzyl derivatives
|
US5283361A
(en)
|
1991-04-23 |
1994-02-01 |
Eli Lilly And Company |
N-hydroxy-N-[3-[2-(halophenylthio)phenyl]prop-2-enyl]ureas as lipoxygenase inhibitors
|
US5130485A
(en)
|
1991-04-23 |
1992-07-14 |
Eli Lilly And Company |
N-hydroxy-N-(3-(2-substituted phenyl)prop-2-enyl)ureas and thioureas useful as 5-lipoxygenase inhibiting agents
|
US5147893A
(en)
|
1991-05-09 |
1992-09-15 |
G. D. Searle & Co. |
Cyclic phenolic thioethers
|
US5114958A
(en)
|
1991-05-09 |
1992-05-19 |
Warner-Lambert Company |
1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents
|
US5442111A
(en)
|
1991-05-24 |
1995-08-15 |
Warner-Lambert Company |
3,5-di-tetriary-4-butyl-4-hydroxyphenyloxy- or tioalkylene N-hydroxyamides, N-hydroxythioamides, N-hydroxyureas, and N-hydroxythioureas as 5-lipoxygenase inhibitors
|
SE9101642D0
(sv)
|
1991-05-30 |
1991-05-30 |
Kabi Pharmacia Ab |
Phospholipids
|
US5215630A
(en)
|
1991-06-04 |
1993-06-01 |
Nippon Suisan Kaisha, Ltd. |
Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
|
DE4123613C1
(es)
|
1991-07-17 |
1993-02-04 |
Gruenenthal Gmbh, 5100 Aachen, De |
|
DE4124345A1
(de)
|
1991-07-23 |
1993-01-28 |
Gruenenthal Gmbh |
Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel
|
WO1993003450A1
(en)
|
1991-07-30 |
1993-02-18 |
North Carolina State University |
Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
|
US5250547A
(en)
|
1991-08-29 |
1993-10-05 |
Syntex (U.S.A.) Inc. |
Benzopyran derivatives
|
US5270319A
(en)
|
1991-09-09 |
1993-12-14 |
Warner-Lambert Company |
5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
|
CA2076257A1
(en)
|
1991-09-13 |
1993-03-14 |
Jan Heeres |
4-¬4-¬4-(4-hydroxyphenyl)-1- piperazinyl|phenyl|-5-methyl-3h -1,2,4-triazol-3-one derivatives
|
DE4133694C2
(de)
|
1991-10-11 |
1993-10-07 |
Fresenius Ag |
Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
|
JP3400466B2
(ja)
|
1991-10-28 |
2003-04-28 |
日本水産株式会社 |
高純度エイコサペンタエン酸またはそのエステルの製造方法
|
US5476944A
(en)
|
1991-11-18 |
1995-12-19 |
G. D. Searle & Co. |
Derivatives of cyclic phenolic thioethers
|
WO1993009774A1
(en)
|
1991-11-18 |
1993-05-27 |
G.D. Searle & Co. |
2-(4-substituted)phenylmethylene derivatives and methods of use
|
US5212189A
(en)
|
1991-12-17 |
1993-05-18 |
Warner-Lambert Company |
Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
|
US5288896A
(en)
|
1992-01-15 |
1994-02-22 |
Warner-Lambert Company |
3,5-di-t-butyl-4-hydroxylphenylmethylhydroxylamines and their derivatives, pharmaceutical compositions, and methods of use therefor
|
DE4204686A1
(de)
|
1992-02-17 |
1993-08-19 |
Gruenenthal Gmbh |
Imidazolylphenolderivate, diese enthaltende arzneimittel sowie ein verfahren zur herstellung dieser verbindungen und arzneimitteln
|
US5196431A
(en)
|
1992-02-24 |
1993-03-23 |
Warner-Lambert Company |
2-substituted amino-4, 6-di-tertiary-buthyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
|
US5220025A
(en)
|
1992-02-24 |
1993-06-15 |
Warner-Lambert Company |
2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
|
US5639782A
(en)
|
1992-03-04 |
1997-06-17 |
Center For Innovative Technology |
Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
|
US5530141A
(en)
|
1992-03-04 |
1996-06-25 |
Center For Innovative Technology |
2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diaryl-1,3-oxathiolanes; and 2,5-diaryl-1,3-oxathiolanes for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
US5187175A
(en)
|
1992-03-06 |
1993-02-16 |
Warner-Lambert Company |
2-carbonyl substituted-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
|
US5595872A
(en)
|
1992-03-06 |
1997-01-21 |
Bristol-Myers Squibb Company |
Nucleic acids encoding microsomal trigyceride transfer protein
|
US5215986A
(en)
|
1992-06-01 |
1993-06-01 |
Warner-Lambert Company |
5-hydroxy-2-pyrimidinylmethylene oxaza heterocycles
|
US5208364A
(en)
|
1992-06-25 |
1993-05-04 |
Bristol-Myers Squibb Co. |
Antibiotic 5-lipoxygenase inhibitors
|
US5314898A
(en)
|
1992-06-29 |
1994-05-24 |
Merck & Co., Inc. |
Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis
|
US5648486A
(en)
|
1992-07-13 |
1997-07-15 |
Cytomed, Inc. |
Compounds and methods for the treatment of inflammatory and immune disorders
|
US5358938A
(en)
|
1992-07-13 |
1994-10-25 |
Cytomed, Inc. |
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
US5463083A
(en)
|
1992-07-13 |
1995-10-31 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
AU666578B2
(en)
|
1992-07-13 |
1996-02-15 |
Cytomed, Inc |
2,5-diaryl tetrahydro-thiophenes, -furans and analogs for the treatment of inflammatory and immune disorders
|
US5434151A
(en)
|
1992-08-24 |
1995-07-18 |
Cytomed, Inc. |
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
US5541218A
(en)
|
1992-07-23 |
1996-07-30 |
Pfizer Inc. |
Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as lipoxygenase inhibitors
|
JPH0649479A
(ja)
|
1992-07-28 |
1994-02-22 |
Maruha Corp |
ω−3不飽和脂肪酸系化合物の安定化法
|
US5240929A
(en)
|
1992-08-03 |
1993-08-31 |
Warner-Lambert Company |
2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
|
US5888541A
(en)
|
1992-08-21 |
1999-03-30 |
Scotia Holdings Plc |
Fatty acid treatment
|
GB9217780D0
(en)
|
1992-08-21 |
1992-10-07 |
Efamol Holdings |
Fatty acid treatment
|
JPH0692847A
(ja)
|
1992-09-11 |
1994-04-05 |
Mochida Pharmaceut Co Ltd |
骨粗鬆症治療剤
|
WO1994010125A1
(en)
|
1992-10-27 |
1994-05-11 |
Sandoz Ltd. |
Glycerin derivatives and uses thereof
|
US5288751A
(en)
|
1992-11-06 |
1994-02-22 |
Abbott Laboratories |
[(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
|
US5314900A
(en)
|
1992-11-19 |
1994-05-24 |
Merck Frosst Canada, Inc. |
Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene biosynthesis
|
US5292900A
(en)
|
1992-12-18 |
1994-03-08 |
Abbott Laboratories |
O-substituted N-hydroxyurea derivatives
|
US5326907A
(en)
|
1992-12-18 |
1994-07-05 |
G. D. Searle & Co. |
2-aminoethanesulfonic acid derivatives of 3,5-disubstituted-4-hydroxyphenolic thioethers
|
GB9300125D0
(en)
|
1993-01-06 |
1993-03-03 |
Scotia Holdings Plc |
Compositions containing esters of unsaturated fatty acids
|
ES2062943B1
(es)
|
1993-03-23 |
1995-11-16 |
Uriach & Cia Sa J |
Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
|
IL109311A0
(en)
|
1993-04-16 |
1994-07-31 |
Lilly Co Eli |
1H-indole-3-acetamide sPla2 inhibitors
|
AP9400632A0
(en)
|
1993-04-29 |
1995-10-07 |
Zeneca Ltd |
Ether derivatives.
|
CA2161777A1
(en)
|
1993-05-10 |
1994-11-24 |
Nancy M. Gray |
Methods and compositions using optically pure (+)-zileuton
|
US6239170B1
(en)
|
1993-05-28 |
2001-05-29 |
Gurpreet S. Ahluwalia |
Inhibition of hair growth
|
WO1994028891A1
(en)
|
1993-06-04 |
1994-12-22 |
Martek Biosciences Corporation |
Method of treating coronary vascular disease using docosahexaenoic acid
|
JPH0738598A
(ja)
|
1993-06-29 |
1995-02-07 |
Toshiba Corp |
ネットワークアダプタ群管理装置
|
US5739135A
(en)
|
1993-09-03 |
1998-04-14 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
GB9318611D0
(en)
|
1993-09-08 |
1993-10-27 |
Sandoz Nutrition Ltd |
Improvements in or relating to organic compounds
|
US5459154A
(en)
|
1993-11-08 |
1995-10-17 |
American Home Products Corporation |
N-hydroxyureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low density lipoprotein
|
ES2087019B1
(es)
|
1994-02-08 |
1997-03-16 |
Bobel246 S L |
Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa.
|
JP3325995B2
(ja)
|
1994-02-28 |
2002-09-17 |
ミサワホーム株式会社 |
パネル接合構造
|
GB9403857D0
(en)
|
1994-03-01 |
1994-04-20 |
Scotia Holdings Plc |
Fatty acid derivatives
|
GB9404483D0
(en)
|
1994-03-08 |
1994-04-20 |
Norsk Hydro As |
Refining marine oil compositions
|
AU1326795A
(en)
|
1994-03-09 |
1995-09-25 |
Pfizer Inc. |
Isoxazoline compounds as 5-lipoxygenase inhibitors
|
US6252084B1
(en)
|
1994-03-15 |
2001-06-26 |
Eli Lilly And Company |
1H-indole-3-acetamide sPLA2 inhibitors
|
WO1995026346A1
(en)
|
1994-03-28 |
1995-10-05 |
Pfizer Inc. |
Benzisothiazoles derivatives as inhibitors of 5-lipoxygenase biosynthesis
|
DK1950200T3
(da)
|
1994-04-01 |
2012-04-10 |
Lilly Co Eli |
[[3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-(PHENYLMETHYL)-11H-INDOL-4-YL]OXY]EDDIKESYREMETHYLESTER SOM sPLA2-INHIBITOR
|
US5385929A
(en)
|
1994-05-04 |
1995-01-31 |
Warner-Lambert Company |
[(Hydroxyphenylamino) carbonyl] pyrroles
|
US5534524A
(en)
|
1994-05-09 |
1996-07-09 |
Board Of Regents, The University Of Texas System |
Suppression of bone resorption by quinolines
|
US5760081A
(en)
|
1994-05-10 |
1998-06-02 |
The General Hospital Corporation |
Omega 3 fatty acids in the prevention of ventricular fibrillation
|
JP3179286B2
(ja)
|
1994-05-19 |
2001-06-25 |
ファイザー製薬株式会社 |
N−ヒドロキシ尿素系抗炎症剤
|
JP3368100B2
(ja)
|
1994-06-02 |
2003-01-20 |
キヤノン株式会社 |
静電荷像現像用トナー
|
US5792776A
(en)
|
1994-06-27 |
1998-08-11 |
Cytomed, Inc., |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US5750565A
(en)
|
1995-05-25 |
1998-05-12 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US5703093A
(en)
|
1995-05-31 |
1997-12-30 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
AU711482B2
(en)
|
1994-06-28 |
1999-10-14 |
Scotia Holdings Plc |
Compositions for treatment of diabetic complications
|
US5641800A
(en)
|
1994-07-21 |
1997-06-24 |
Eli Lilly And Company |
1H-indole-1-functional sPLA2 inhibitors
|
US6214876B1
(en)
|
1994-07-21 |
2001-04-10 |
Eli Lilly And Company |
Indene-1-acetamide sPLA2 inhibitors
|
JPH0850637A
(ja)
|
1994-08-04 |
1996-02-20 |
Toshiba Corp |
帳票類取扱装置
|
IT1274734B
(it)
|
1994-08-25 |
1997-07-24 |
Prospa Bv |
Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
|
US5674488A
(en)
|
1994-10-07 |
1997-10-07 |
Reich; John J. |
Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
|
US5635514A
(en)
|
1994-10-25 |
1997-06-03 |
G. D. Searle & Company |
Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as 5-lipoxgenase inhibitors
|
JPH08193074A
(ja)
|
1994-11-18 |
1996-07-30 |
Nippon Bayeragrochem Kk |
除草性1−シクロプロピルテトラゾリノン類
|
JPH08165267A
(ja)
|
1994-12-14 |
1996-06-25 |
Yakult Honsha Co Ltd |
ジアリルヘプタノイド誘導体およびこれを含有する抗炎症剤
|
JP2780154B2
(ja)
|
1995-02-17 |
1998-07-30 |
株式会社ヤクルト本社 |
ヨーグルト
|
US5514703A
(en)
|
1995-03-13 |
1996-05-07 |
Eli Lilly And Company |
Benzothiophene compounds useful for inhibiting lipoxygenase
|
JPH0840981A
(ja)
|
1995-03-24 |
1996-02-13 |
Nissui Pharm Co Ltd |
エイコサペンタエノイルグリセライド
|
US5516789A
(en)
|
1995-04-12 |
1996-05-14 |
Abbott Laboratories |
Lipoxygenase and cyclooxygenase inhibiting compounds
|
MY118354A
(en)
|
1995-05-01 |
2004-10-30 |
Scarista Ltd |
1,3-propane diol derivatives as bioactive compounds
|
GB9509764D0
(en)
|
1995-05-15 |
1995-07-05 |
Tillotts Pharma Ag |
Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
|
CA2223154A1
(en)
|
1995-06-02 |
1996-12-05 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
EP0833622B8
(en)
|
1995-06-12 |
2005-10-12 |
G.D. Searle & Co. |
Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
|
JPH0959206A
(ja)
|
1995-08-25 |
1997-03-04 |
Nippon Oil & Fats Co Ltd |
エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法
|
JP3552810B2
(ja)
|
1995-09-27 |
2004-08-11 |
松下電器産業株式会社 |
部品供給部の部品一括交換方法と装置
|
GB9519661D0
(en)
|
1995-09-27 |
1995-11-29 |
Scotia Holdings Plc |
Fatty acid treatment
|
US6635614B1
(en)
|
1995-11-09 |
2003-10-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Use of lecithin-cholesterol acyltransferase (LCAT) to reduce accumulation of cholesterol
|
US5763496A
(en)
|
1995-11-27 |
1998-06-09 |
The Research Foundation Of State University Of New York |
Prevention of atherosclerosis using NADPH oxidase inhibitors
|
US5762413A
(en)
|
1996-01-29 |
1998-06-09 |
Alternate Realities Corporation |
Tiltable hemispherical optical projection systems and methods having constant angular separation of projected pixels
|
US6231189B1
(en)
|
1996-01-29 |
2001-05-15 |
Elumens Corporation |
Dual polarization optical projection systems and methods
|
WO1997029776A1
(en)
|
1996-02-13 |
1997-08-21 |
G.D. Searle & Co. |
Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
|
WO1997039759A2
(en)
|
1996-04-24 |
1997-10-30 |
Brigham And Women's Hospital |
Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
|
US6077828A
(en)
|
1996-04-25 |
2000-06-20 |
Abbott Laboratories |
Method for the prevention and treatment of cachexia and anorexia
|
US6090547A
(en)
|
1997-04-25 |
2000-07-18 |
Brigham & Women's Hospital |
Identification of asthma patients who are candidates for effective treatment with 5-lipoxygenase inhibitors
|
EP0896633A2
(en)
|
1996-05-06 |
1999-02-17 |
Brigham And Women's Hospital |
5-lipoxygenase gene polymorphisms and their use in classifying patients
|
US5827875A
(en)
|
1996-05-10 |
1998-10-27 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
US5885983A
(en)
|
1996-05-10 |
1999-03-23 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
US6248398B1
(en)
|
1996-05-22 |
2001-06-19 |
Applied Materials, Inc. |
Coater having a controllable pressurized process chamber for semiconductor processing
|
US6776986B1
(en)
|
1996-06-06 |
2004-08-17 |
Novartis Ag |
Inhibition of HIV-1 replication by antisense RNA expression
|
TW425285B
(en)
|
1996-06-10 |
2001-03-11 |
Viva America Marketing Inc |
Fish oil and garlic nutritive supplement
|
US5965619A
(en)
|
1996-06-13 |
1999-10-12 |
Cell Pathways Inc. |
Method for treating patients having precancerous lesions with substituted indene derivatives
|
US5998477A
(en)
|
1996-06-13 |
1999-12-07 |
Cell Pathways Inc. |
Substituted methoxy benzylidene indenyl-acetic and propionic acids for treating patients with precancerous lesions
|
US6121321A
(en)
|
1996-06-13 |
2000-09-19 |
Cell Pathways, Inc. |
Substituted methoxy benzylidene indenyl acetic and propionic acids for treating patients with precancerous lesions
|
US6063818A
(en)
|
1996-06-13 |
2000-05-16 |
Cell Pathways Inc. |
Substituted benzylidene indenyl formamides, acetamides and propionamides
|
US5861399A
(en)
|
1996-07-17 |
1999-01-19 |
Heart Care Partners |
Methods and compositions for the rapid and enduring relief of inadequate myocardial function
|
US6005000A
(en)
|
1996-08-22 |
1999-12-21 |
Oxis International, Inc. |
5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
|
DE19636150A1
(de)
|
1996-09-06 |
1998-03-12 |
Asta Medica Ag |
N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
|
US20020055539A1
(en)
|
1996-10-02 |
2002-05-09 |
Bockow Barry I. |
Compositions and methods for treating cardiovascular conditions
|
NZ334852A
(en)
|
1996-10-11 |
2001-05-25 |
Scotia Holdings Plc |
Use and preparation containing eicosapentaenoic acid (EPA; 20:5n-3) for treating schizophrenia
|
US6426335B1
(en)
|
1997-10-17 |
2002-07-30 |
Gilead Sciences, Inc. |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
US6569539B2
(en)
|
1996-10-30 |
2003-05-27 |
Tetra Level Holdings & Finance S.A. |
Gas barrier packaging laminate method for production thereof and packaging containers
|
US6713645B1
(en)
|
1996-10-30 |
2004-03-30 |
Eli Lilly And Company |
Substituted tricyclics
|
US6177440B1
(en)
|
1996-10-30 |
2001-01-23 |
Eli Lilly And Company |
Substituted tricyclics
|
JP4176166B2
(ja)
*
|
1996-11-15 |
2008-11-05 |
持田製薬株式会社 |
横紋筋融解症治療剤
|
EP0843972B1
(en)
|
1996-11-20 |
2002-07-31 |
N.V. Nutricia |
Nutritional composition comprising fats for the treatment of the metabolic syndrome
|
US6353128B1
(en)
|
1996-12-03 |
2002-03-05 |
Eli Lilly And Company |
Phenyl acetamides as sPLA2 inhibitors
|
US5909734A
(en)
|
1996-12-03 |
1999-06-08 |
Regents Of The University Of Michigan |
Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
|
US5916922A
(en)
|
1996-12-03 |
1999-06-29 |
Eli Lilly And Company |
Phenyl glyoxamides as SPLA2 inhibitors
|
ID18983A
(id)
|
1996-12-04 |
1998-05-28 |
Lilly Co Eli |
Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
|
US6011049A
(en)
|
1997-02-19 |
2000-01-04 |
Warner-Lambert Company |
Combinations for diabetes
|
AU6415998A
(en)
|
1997-04-18 |
1998-11-13 |
Pfizer Inc. |
Process and intermediates for the preparation of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide
|
US6177415B1
(en)
|
1997-04-21 |
2001-01-23 |
The United States Of America As Represented By The Secretary Of Agriculture |
Bacteriohopanetetrol and related compounds useful for modulation of lipoxygenase activity and anti-inflammatory applications
|
JP4231559B2
(ja)
|
1997-04-23 |
2009-03-04 |
オリザ油化株式会社 |
リポキシゲナーゼ阻害剤
|
WO1998047507A1
(en)
|
1997-04-24 |
1998-10-29 |
Shionogi & Co., Ltd. |
Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
|
US20030008816A1
(en)
|
1997-05-28 |
2003-01-09 |
Pilon Aprile L. |
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
|
US20060025348A1
(en)
|
1997-05-28 |
2006-02-02 |
Pilon Aprile L |
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
|
US20020169108A1
(en)
|
1997-05-28 |
2002-11-14 |
Pilon Aprile L. |
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
US6767739B2
(en)
|
2001-07-30 |
2004-07-27 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microsomal triglyceride transfer protein expression
|
CA2301586A1
(en)
|
1997-08-28 |
1999-03-04 |
William Louis Macias |
Method for treatment of non-rheumatoid arthritis
|
IT1304595B1
(it)
|
1997-08-29 |
2001-03-19 |
Giorgio Endrici |
Inibitore della 5-lipoossigenasi
|
JPH1180083A
(ja)
|
1997-09-10 |
1999-03-23 |
Nof Corp |
エイコサペンタエン酸エステルの製造方法
|
US6218524B1
(en)
|
1997-09-16 |
2001-04-17 |
Eurona Medical Ab |
Genetic polymorphisms in the microsomal triglyceride transfer protein promoter and uses thereof
|
CA2308443A1
(en)
|
1997-10-27 |
1999-05-06 |
Michael Lyle Denney |
Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
|
EP1030661A4
(en)
|
1997-10-27 |
2002-07-17 |
Lilly Co Eli |
N, N-DIETHYLGLYCOLAMIDOESTER OF INDOLS AS PRELIMINARY MEDICINE OF SPLA 2 INHIBITORS
|
US6440961B1
(en)
|
1997-10-27 |
2002-08-27 |
Dr. Reddy's Research Foundation |
Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
|
DE69825173T2
(de)
|
1997-10-30 |
2005-08-25 |
Morishita Jintan Co. Ltd. |
Doppelschichtige kapsel von ungesättigten fettsäuren oder deren derivate und verfahren zu deren herstellung
|
JP2001522883A
(ja)
|
1997-11-14 |
2001-11-20 |
イーライ・リリー・アンド・カンパニー |
アルツハイマー病の処置
|
EP1043991A4
(en)
|
1997-11-14 |
2005-02-02 |
Lilly Co Eli |
TREATMENT OF ALZHEIMER DISEASE
|
KR100586754B1
(ko)
|
1997-11-25 |
2006-06-08 |
워너-램버트 캄파니 엘엘씨 |
지단백질 산화의 억제
|
US6121323A
(en)
|
1997-12-03 |
2000-09-19 |
3M Innovative Properties Company |
Bishydroxyureas
|
EP1039893B1
(en)
|
1997-12-10 |
2011-02-02 |
Cyclosporine Therapeutics Limited |
Pharmaceutical compositions containing an omega-3 fatty acid oil
|
US5948779A
(en)
|
1997-12-12 |
1999-09-07 |
Cell Pathways, Inc. |
Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
|
US6916841B2
(en)
|
1998-02-25 |
2005-07-12 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
EA003864B1
(ru)
|
1998-03-03 |
2003-10-30 |
ШИОНОГИ энд КО.,ЛТД. |
КОМПОЗИЦИЯ И СПОСОБ ПРИГОТОВЛЕНИЯ ФАРМАЦЕВТИЧЕСКОГО СОСТАВА, ЛИОФИЛИЗИРОВАННАЯ КОМПОЗИЦИЯ И ЕЕ ПРИМЕНЕНИЕ, СПОСОБ ИНГИБИРОВАНИЯ sPLA2-ОПОСРЕДОВАННОГО ВЫСВОБОЖДЕНИЯ ЖИРНОЙ КИСЛОТЫ, СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩИХ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ СЕПСИСА, ЗАКРЫТАЯ ЕМКОСТЬ
|
CZ300706B6
(cs)
|
1998-03-31 |
2009-07-22 |
The Institutes For Pharmaceutical Discovery, Inc. |
Derivát indolalkanové kyseliny a lécivo pro prevenci nebo zmírnení chronických komplikací vznikajících z diabetes mellitus
|
CA2326522A1
(en)
|
1998-03-31 |
1999-10-14 |
Shionogi & Co., Ltd. |
Pyrrolo[1,2-a]pyrazine spla2 inhibitor
|
US6028116A
(en)
|
1998-04-03 |
2000-02-22 |
Cell Pathways, Inc. |
Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
|
US6407261B1
(en)
|
1998-04-17 |
2002-06-18 |
Eli Lilly And Company |
Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
|
DZ2770A1
(fr)
|
1998-04-17 |
2003-12-01 |
Lilly Co Eli |
Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
|
CN1299348A
(zh)
|
1998-05-01 |
2001-06-13 |
伊莱利利公司 |
用于治疗疾病的sPLA2抑制剂化合物
|
CA2332528A1
(en)
|
1998-05-21 |
1999-11-25 |
Shionogi & Co., Ltd. |
Pyrrolo[1,2-b]pyridazine spla2 inhibitory
|
WO1999063929A2
(en)
|
1998-06-08 |
1999-12-16 |
Advanced Medicine, Inc. |
Multibinding inhibitors of microsomal triglyceride transferase protein
|
US20020045271A1
(en)
|
1998-06-10 |
2002-04-18 |
Licata And Tyrrell P.C. |
Compounds and methods for identifying compounds that interact with microsomal triglyceride transfer protein binding sites on apolipoprotein b and modulate lipid biosynthesis
|
JP2002519325A
(ja)
|
1998-06-30 |
2002-07-02 |
イーライ・リリー・アンド・カンパニー |
二環性sPLA2インヒビター
|
DE19830375A1
(de)
|
1998-07-08 |
2000-01-13 |
K D Pharma Bexbach Gmbh |
Mikroverkapselte ungesättigte Fettsäure oder Fettsäureverbindung oder Mischung aus Fettsäuren und/oder Fettsäureverbindungen
|
ES2263283T3
(es)
|
1998-08-03 |
2006-12-01 |
ELI LILLY & COMPANY |
Inhibidores de spla2 indol.
|
JP2002522386A
(ja)
|
1998-08-03 |
2002-07-23 |
イーライ・リリー・アンド・カンパニー |
インドールsPLA2インヒビター
|
US6576654B1
(en)
|
1998-09-23 |
2003-06-10 |
Eli Lilly And Company |
Method for the treatment of cystic fibrosis
|
US6221880B1
(en)
|
1998-10-09 |
2001-04-24 |
Schering Corporation |
Composition and method for treating allergic diseases
|
EP1157704B1
(en)
|
1998-10-14 |
2006-06-14 |
Shionogi & Co., Ltd. |
Spla2 inhibitors for the treatment of ischaemic reperfusion injury
|
US20030008914A1
(en)
|
1998-10-16 |
2003-01-09 |
C. Grace Yeh |
Pharmaceutical formulations useful to treat inflammatory and immune disorders
|
US6248553B1
(en)
|
1998-10-22 |
2001-06-19 |
Atairgin Technologies, Inc. |
Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids
|
NZ500703A
(en)
|
1998-11-04 |
2001-06-29 |
F |
Preparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract
|
TNSN99224A1
(fr)
|
1998-12-01 |
2005-11-10 |
Inst For Pharm Discovery Inc |
Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
|
US20020055529A1
(en)
*
|
1998-12-02 |
2002-05-09 |
Bisgaier Charles Larry |
Method for treating alzheimer's disease
|
DE69933471T2
(de)
|
1998-12-17 |
2007-08-30 |
Xenogen Corp., Alameda |
Unblutige bestimmung einer physiologischen reaktion in einem säugetier
|
US6391908B1
(en)
|
1998-12-22 |
2002-05-21 |
Eli Lilly And Company |
Oxime amide indole type sPLA2 inhibitors
|
US6194585B1
(en)
|
1998-12-22 |
2001-02-27 |
Pfizer Inc. |
Process for preparing 5-lipoxygenase inhibitors
|
ATE247119T1
(de)
|
1998-12-22 |
2003-08-15 |
Lilly Co Eli |
Substituierte pyrroloindole
|
WO2000038725A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations for cardiovascular indications
|
GB9901809D0
(en)
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
CA2260397A1
(en)
|
1999-01-29 |
2000-07-29 |
Atlantis Marine Inc. |
Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
|
US20030104048A1
(en)
|
1999-02-26 |
2003-06-05 |
Lipocine, Inc. |
Pharmaceutical dosage forms for highly hydrophilic materials
|
US6193999B1
(en)
|
1999-03-01 |
2001-02-27 |
Banner Pharmacaps, Inc. |
Gum acacia substituted soft gelatin capsules
|
CA2366318A1
(en)
|
1999-03-03 |
2000-09-08 |
Ida Royalty Aps |
Novel pharmaceutical, dietary and cosmetic compositions comprising zinger officinale roscoe, eicosapentaenoic acid and/or docosahexaenoic acid
|
DK1166652T4
(en)
|
1999-03-04 |
2016-10-24 |
Suntory Holdings Ltd |
The use of material containing 4, 7, 10, 13, 16-docosapentaenoic acid
|
US20020110523A1
(en)
|
1999-03-23 |
2002-08-15 |
Cornelis Kluft |
Methods for screening or monitoring the risk of cardiovascular disease relating to sex steroid compound or composition intake and methods for screening sex steroid compound
|
US20020054871A1
(en)
|
1999-04-12 |
2002-05-09 |
Yadong Huang |
Methods and compositions for use in the treatment of hyperlipidemia
|
US6380397B1
(en)
|
1999-04-15 |
2002-04-30 |
Eli Lilly And Company |
Process for preparing 4-substituted-1H-indole-3-glyoxamides
|
US6274578B1
(en)
|
1999-04-20 |
2001-08-14 |
Eli Lilly And Company |
sPLA2 inhibitor ester
|
JP2001025519A
(ja)
|
1999-05-11 |
2001-01-30 |
Mamiya Op Co Ltd |
ゴルフクラブ用シャフト
|
US6140327A
(en)
|
1999-05-12 |
2000-10-31 |
Eli Lilly And Company |
Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
|
US7112609B2
(en)
|
1999-06-01 |
2006-09-26 |
Drugtech Corporation |
Nutritional supplements
|
US6207699B1
(en)
|
1999-06-18 |
2001-03-27 |
Richard Brian Rothman |
Pharmaceutical combinations for treating obesity and food craving
|
CA2311974A1
(en)
|
1999-06-28 |
2000-12-28 |
Nisshin Flour Milling Co., Ltd. |
Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
|
GB9916536D0
(en)
*
|
1999-07-14 |
1999-09-15 |
Scarista Limited |
Nutritional or pharmaceutical compositions
|
US6706752B1
(en)
|
1999-07-19 |
2004-03-16 |
Eli Lilly And Company |
sPLA2 inhibitors
|
US6703385B1
(en)
|
1999-07-19 |
2004-03-09 |
Shionogi & Co., Ltd. |
Tricyclic compounds having sPLA2-inhibitory activities
|
DE19933926A1
(de)
|
1999-07-20 |
2001-01-25 |
Boehringer Ingelheim Pharma |
Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
|
DE59914760D1
(de)
|
1999-07-28 |
2008-06-26 |
Swiss Caps Rechte & Lizenzen |
Präparat zur Verwendung als Medikament und/oder Nahrungsmittelergänzung
|
AU6023200A
(en)
|
1999-08-02 |
2001-02-19 |
Shionogi & Co., Ltd. |
Tricyclic compounds having spla2-inhibitory activities
|
WO2001012600A1
(en)
|
1999-08-12 |
2001-02-22 |
Cor Therapeutics, Inc. |
INHIBITORS OF FACTOR Xa
|
WO2001014378A1
(fr)
|
1999-08-23 |
2001-03-01 |
Shionogi & Co., Ltd. |
DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
|
CA2382262C
(en)
|
1999-08-30 |
2004-12-07 |
Ocean Nutrition Canada Ltd. |
A nutritional supplement for lowering serum triglyceride and cholesterol levels
|
US6344563B1
(en)
|
1999-08-31 |
2002-02-05 |
Timothy Norris |
Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
|
US6831095B1
(en)
|
1999-09-20 |
2004-12-14 |
Eli Lilly And Company |
Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
|
US6872557B1
(en)
|
1999-09-21 |
2005-03-29 |
Shionogi & Co., Ltd. |
Gene encoding novel human secretory phospholipase A2
|
AU1201401A
(en)
|
1999-10-15 |
2001-04-30 |
Du Pont Pharmaceuticals Company |
Benzylcycloalkyl amines as modulators of chemokine receptor activity
|
US6261607B1
(en)
|
1999-10-19 |
2001-07-17 |
Thomas Newmark |
Composition for promoting prostate health containing selenium and herbal extracts
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
CA2325358C
(en)
|
1999-11-10 |
2005-08-02 |
Pfizer Products Inc. |
7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
|
WO2001036420A1
(fr)
|
1999-11-15 |
2001-05-25 |
Shionogi & Co., Ltd. |
Derives d'aza-indolizine tricyclique ayant un effet inhibiteur sur spla¿2?
|
JP4170542B2
(ja)
|
1999-11-18 |
2008-10-22 |
日油株式会社 |
高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
|
DE19962300A1
(de)
|
1999-12-23 |
2001-06-28 |
Asta Medica Ag |
Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
|
EP1259484B1
(en)
|
2000-01-18 |
2005-05-18 |
Novartis AG |
Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
|
EP1125914A1
(en)
|
2000-02-14 |
2001-08-22 |
Nisshin Flour Milling Co., Ltd. |
Process for separating and purifying eicosapentaenoic acid or its ester
|
DE10007203A1
(de)
|
2000-02-17 |
2001-08-23 |
Asta Medica Ag |
Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
|
SE0000754D0
(sv)
|
2000-03-07 |
2000-03-07 |
Amersham Pharm Biotech Ab |
Mass spectral peak identification
|
CN1768735A
(zh)
|
2000-03-17 |
2006-05-10 |
味之素株式会社 |
糖尿病性合并症和神经障碍用的药剂及其应用
|
WO2001070130A2
(en)
|
2000-03-22 |
2001-09-27 |
Creighton University |
Compositions derived from modiolus modiolus and methods for making and using same
|
AU2001251665A1
(en)
|
2000-04-17 |
2001-10-30 |
Glaxo Group Limited |
Medicine response assay in respiratory disease
|
US6987105B2
(en)
|
2000-04-28 |
2006-01-17 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of thienotriazolodiazepines
|
DE10022925A1
(de)
|
2000-05-11 |
2001-11-15 |
Basf Ag |
Substituierte Indole als PARP-Inhibitoren
|
EP1157692B1
(en)
|
2000-05-22 |
2005-10-05 |
Pro Aparts - Investimentos E Consultoria Lda |
Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
|
GB0013378D0
(en)
|
2000-06-01 |
2000-07-26 |
Glaxo Group Ltd |
Use of therapeutic benzamide derivatives
|
US6620821B2
(en)
*
|
2000-06-15 |
2003-09-16 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
DE10030375A1
(de)
|
2000-06-21 |
2002-01-03 |
Bayer Ag |
Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
|
WO2002000641A2
(en)
|
2000-06-28 |
2002-01-03 |
Eli Lilly And Company |
Spla2 inhibitors
|
GB0016045D0
(en)
|
2000-06-29 |
2000-08-23 |
Laxdale Limited |
Therapeutic combinations of fatty acids
|
US20040102442A1
(en)
|
2000-06-29 |
2004-05-27 |
Kohji Hanasaki |
Remedies for alzheimer's disease
|
AU2001267824A1
(en)
|
2000-06-29 |
2002-01-08 |
Shionogi And Co., Ltd. |
Remedies for cancer
|
AU2001267825A1
(en)
|
2000-06-29 |
2002-01-08 |
Shionogi And Co., Ltd. |
Remedies for cirrhosis
|
AU2001267823A1
(en)
|
2000-06-29 |
2002-01-08 |
Shionogi And Co., Ltd. |
Compounds exhibiting x-type spla2 inhibiting effect
|
GB0016452D0
(en)
|
2000-07-04 |
2000-08-23 |
Kilgowan Limited |
Vitamin K and essential fatty acids
|
US20020032238A1
(en)
|
2000-07-08 |
2002-03-14 |
Henning Priepke |
Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
|
WO2002008189A1
(en)
|
2000-07-24 |
2002-01-31 |
The University Of Queensland |
Compounds and inhibitors of phospholipases
|
US6835742B2
(en)
|
2000-08-04 |
2004-12-28 |
R. Preston Mason |
Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release
|
JP4391673B2
(ja)
|
2000-08-08 |
2009-12-24 |
花王株式会社 |
油脂組成物
|
US6417367B1
(en)
|
2000-08-11 |
2002-07-09 |
Pfizer Inc. |
Methods of making quinoline amides
|
AU2001284876A1
(en)
|
2000-08-15 |
2002-02-25 |
South Alabama Medical Science Foundation |
Treating sickle cell disease
|
SK1742003A3
(en)
|
2000-08-15 |
2004-06-08 |
Pfizer Prod Inc |
Therapeutic combinations of a CETP inhibitor and atorvastatin
|
US6383482B1
(en)
|
2000-08-24 |
2002-05-07 |
Vitacost.Com, Inc. |
Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
|
US20120237626A9
(en)
|
2000-12-05 |
2012-09-20 |
Palu Afa Kehaati |
Profiles of lipid proteins and inhibiting HMG-CoA reductase
|
US6872743B2
(en)
|
2000-12-18 |
2005-03-29 |
Eli Lilly And Company |
sPLA2 inhibitors
|
JP2004520363A
(ja)
|
2000-12-18 |
2004-07-08 |
イーライ・リリー・アンド・カンパニー |
新規なsPLA2インヒビター
|
WO2002050030A2
(en)
|
2000-12-18 |
2002-06-27 |
Eli Lilly And Company |
Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
|
EP1349832A2
(en)
|
2000-12-18 |
2003-10-08 |
Eli Lilly And Company |
Substituted benzoindoles as spla2 inhibitors
|
GB0101198D0
(en)
|
2001-01-17 |
2001-02-28 |
Scherer Technologies Inc R P |
Ingestible compositions containing an odoriferous oil
|
JP2005503533A
(ja)
|
2001-01-19 |
2005-02-03 |
ケンブリッジ サイエンティフィック, インコーポレイテッド |
骨粗鬆症の診断方法および処置方法
|
ITMI20010129A1
(it)
|
2001-01-25 |
2002-07-25 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
|
WO2002062825A2
(en)
|
2001-02-08 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Detection of polymorphisms in the human 5-lipoxygenase gene
|
TWI314457B
(es)
|
2001-03-19 |
2009-09-11 |
Shionogi & Co |
|
WO2002079154A1
(en)
|
2001-03-28 |
2002-10-10 |
Eli Lilly And Company |
Substituted carbazoles as inhibitors of spla2
|
US7524635B2
(en)
|
2003-04-17 |
2009-04-28 |
Biosite Incorporated |
Methods and compositions for measuring natriuretic peptides and uses thereof
|
GB0111282D0
(en)
|
2001-05-09 |
2001-06-27 |
Laxdale Ltd |
Potentiation of therapeutic effects of fatty acids
|
IL143379A
(en)
|
2001-05-24 |
2013-11-28 |
Yissum Res Dev Co |
Oligonucleotide against human ache isoform r and its uses
|
CA2449199A1
(en)
|
2001-05-30 |
2002-12-05 |
Laxdale Limited |
Coenzyme q and eicosapentaenoic acid (epa)
|
US7901713B2
(en)
|
2001-06-20 |
2011-03-08 |
Metaproteomics, Llc |
Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
|
US6756399B2
(en)
|
2001-06-29 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
|
US6730694B1
(en)
|
2001-07-20 |
2004-05-04 |
Eli Lilly And Company |
sPLA2 inhibitors
|
US20120214771A1
(en)
|
2001-07-27 |
2012-08-23 |
Fontini Sampalis |
Compositions for treatment of cardiometabolic disorders
|
US7160909B2
(en)
|
2001-08-09 |
2007-01-09 |
Eli Lilly And Company |
Cyclopenta[b]indole derivatives as sPLA2 inhibitors
|
JP2005527466A
(ja)
|
2001-08-09 |
2005-09-15 |
イーライ・リリー・アンド・カンパニー |
sPLA2インヒビターとしてのシクロヘプトBインドール誘導体
|
AU2002323474B2
(en)
|
2001-09-13 |
2006-10-05 |
Synta Pharmaceuticals Corp |
3-glyoxlylamideindoles for treating cancer
|
NZ531700A
(en)
|
2001-09-13 |
2006-10-27 |
Synta Pharmaceuticals Corp |
1-Glyoxylamide indolizines for treating cancer
|
ITMI20012384A1
(it)
|
2001-11-12 |
2003-05-12 |
Quatex Nv |
Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
|
WO2003043570A2
(en)
|
2001-11-15 |
2003-05-30 |
Galileo Laboratories, Inc. |
Formulations and methods for treatment or amelioration of inflammatory conditions
|
US20040018248A1
(en)
|
2001-11-29 |
2004-01-29 |
Adrianne Bendich |
Composition containing statins and calcium for improved cardiovascular health
|
US20040033506A1
(en)
|
2001-11-30 |
2004-02-19 |
Dennis Farrelly |
Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
|
US7101875B2
(en)
|
2001-12-03 |
2006-09-05 |
Wyeth |
Methods for treating arthritic disorders
|
US6797708B2
(en)
|
2001-12-03 |
2004-09-28 |
Wyeth |
Inhibitors of cytosolic phospholipase A2
|
US6984735B2
(en)
|
2001-12-03 |
2006-01-10 |
Wyeth |
Process for making an aldehyde
|
US6635771B2
(en)
|
2001-12-03 |
2003-10-21 |
Wyeth |
N-benzhydryl indole compounds
|
TWI323658B
(en)
|
2001-12-06 |
2010-04-21 |
Nat Health Research Institutes |
Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
|
US6992100B2
(en)
|
2001-12-06 |
2006-01-31 |
Eli Lilly And Company |
sPLA2 inhibitors
|
ITMI20020269A1
(it)
|
2002-02-12 |
2003-08-12 |
Victorix Assets Ltd |
Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
|
JP2003306690A
(ja)
|
2002-02-18 |
2003-10-31 |
Nooburu:Kk |
多価不飽和脂肪酸含有油脂組成物
|
HUP0200686A2
(hu)
|
2002-02-22 |
2003-09-29 |
EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. |
Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül
|
US20030166614A1
(en)
|
2002-03-01 |
2003-09-04 |
Harrison Stanley F. |
Method for reducing cholesterol and triglycerides
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
DE60328676D1
(de)
|
2002-04-30 |
2009-09-17 |
Unigen Pharmaceuticals Inc |
Formulierung eines gemisches aus flavonoiden und flavanen mit freiem b ring als therapeutisches mittel
|
CA2485116C
(en)
|
2002-05-03 |
2013-02-05 |
Pronova Biocare As |
Use of epa and dha in secondary prevention
|
ES2524000T3
(es)
|
2002-06-05 |
2014-12-03 |
Teva Czech Industries S.R.O. |
Reducción de la reticulación de la gelatina
|
US20030092767A1
(en)
|
2002-06-07 |
2003-05-15 |
Macias William Louis |
Combination therapy for the treatment of inflammatory and respiratory diseases
|
CA2390820A1
(en)
|
2002-06-17 |
2003-12-17 |
St. Vincent's Hospital Sydney Limited |
Methods of diagnosis, prognosis and treatment of cardiovascular disease
|
US20040077691A1
(en)
|
2002-06-21 |
2004-04-22 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
US6620813B1
(en)
|
2002-06-21 |
2003-09-16 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
US20040001874A1
(en)
|
2002-06-24 |
2004-01-01 |
Vital Living, Inc. |
Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
|
US6653311B1
(en)
|
2002-06-25 |
2003-11-25 |
Board Of Supervisors Of Louisiana State University |
5-lipoxygenase inhibitors: (2-azinylamino) quinone derivatives
|
AU2003247685A1
(en)
|
2002-07-02 |
2004-01-23 |
Galileo Pharmaceuticals, Inc. |
Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
|
US20060211761A1
(en)
|
2002-07-08 |
2006-09-21 |
Yatendra Kumar |
Hmg-coa-reductase inhibitors
|
US20080200453A1
(en)
|
2002-07-29 |
2008-08-21 |
Cincotta Anthony H |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
US20030087944A1
(en)
|
2002-08-05 |
2003-05-08 |
Macias William Louis |
Method for the treatment of renal dysfunction with spla2 inhibitors
|
CN1303993C
(zh)
|
2002-08-20 |
2007-03-14 |
日研化学株式会社 |
软胶囊制剂
|
DE20214847U1
(de)
|
2002-09-24 |
2004-02-19 |
Voss Automotive Gmbh |
Anschlußvorrichtung für Rohrleitungen
|
KR100539027B1
(ko)
|
2002-10-18 |
2005-12-26 |
현대모비스 주식회사 |
차량의 조향각 검출 장치
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
US8106019B2
(en)
|
2002-11-15 |
2012-01-31 |
Philadelphia Health & Education Corporation |
CHEC-7 a novel sPLA2 inhibitor
|
US7528112B2
(en)
|
2002-11-15 |
2009-05-05 |
Drexel University |
Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
|
US8017651B2
(en)
|
2002-11-22 |
2011-09-13 |
Bionexus, Ltd. |
Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
|
CN100352889C
(zh)
|
2002-11-22 |
2007-12-05 |
日本水产株式会社 |
高氧化稳定性的含有双键有机物的组合物
|
ITMI20022511A1
(it)
*
|
2002-11-26 |
2004-05-27 |
Victorix Assets Ltd |
Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
|
GB0228079D0
(en)
|
2002-12-02 |
2003-01-08 |
Laxdale Ltd |
Huntington's Disease
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
US20040198800A1
(en)
|
2002-12-19 |
2004-10-07 |
Geoffrey Allan |
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
|
CA2510815A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Microsomal triglyceride transfer protein inhibitors
|
CA2505604A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Microsomal triglyceride transfer protein inhibitors
|
CA2512666A1
(en)
|
2003-01-08 |
2004-07-29 |
Flacco-Nesselroad Family Trust |
Combination therapy for anticoagulation
|
WO2004063197A1
(en)
|
2003-01-09 |
2004-07-29 |
Fujisawa Pharmaceutical Co., Ltd. |
Pyrrolopyridazine derivatives
|
GB0301701D0
(en)
|
2003-01-24 |
2003-02-26 |
Ensay Ltd |
Psoriasis and Eicosapentaenoic acid
|
EP1587377A2
(en)
|
2003-01-31 |
2005-10-26 |
The Procter & Gamble Company |
Means for improving the appearance of mammalian keratinous tissue
|
WO2004069238A1
(ja)
|
2003-02-07 |
2004-08-19 |
Mochida Pharmaceutical Co., Ltd. |
くも膜下出血の予後改善剤
|
EP1596854A4
(en)
|
2003-02-14 |
2007-06-06 |
Childrens Hosp & Res Ct Oak |
TREATMENT OF DISEASES RELATED TO REDUCED STICK OXIDE BIOVERABILITY, INCLUDING INCREASED ARGINASE
|
EP1595539A4
(en)
|
2003-02-21 |
2007-04-11 |
Mochida Pharm Co Ltd |
DRUGS TO REDUCE THE SIDE EFFECTS OF RIBAVIRIN INTERFERON COMBINATION THERAPY
|
AU2004216856A1
(en)
|
2003-03-05 |
2004-09-16 |
Solvay Pharmaceuticals Gmbh |
Use of omega-3-fatty acids in the treatment of diabetic patients
|
AU2004222633B2
(en)
|
2003-03-18 |
2008-05-01 |
Nestec S.A. |
Compositions comprising fatty acids and amino acids
|
US20050090426A1
(en)
|
2003-03-24 |
2005-04-28 |
Blumberg Richard S. |
Methods of inhibiting inflammation
|
US20050234073A1
(en)
|
2003-03-24 |
2005-10-20 |
Blumberg Richard S |
Methods of inhibiting inflammation
|
US7030112B2
(en)
|
2003-03-25 |
2006-04-18 |
Bristol-Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
US20070066577A1
(en)
|
2003-04-03 |
2007-03-22 |
Hea Young Park Choo |
Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
|
US7329682B2
(en)
|
2003-04-03 |
2008-02-12 |
Ewha University-Industry Collaboration Foundation |
Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7579433B2
(en)
|
2003-04-30 |
2009-08-25 |
National University Of Singapore |
Methods and compositions for treatment of arthritis and cancer
|
US7176281B2
(en)
|
2003-04-30 |
2007-02-13 |
National University Of Singapore |
Phospholipase A2-inhibitory peptide with anti-arthritic and neuroprotective activities
|
EP1479677A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
New indole derivatives as factor xa inhibitors
|
US6846942B2
(en)
|
2003-05-20 |
2005-01-25 |
David Rubin |
Method for preparing pure EPA and pure DHA
|
US20040235807A1
(en)
|
2003-05-21 |
2004-11-25 |
Weinrich Karl P. |
Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
|
US7205329B2
(en)
|
2003-05-30 |
2007-04-17 |
Microbia, Inc. |
Modulators of CRTH2 activity
|
JP4870430B2
(ja)
|
2003-06-20 |
2012-02-08 |
持田製薬株式会社 |
下肢静脈瘤予防・治療用組成物
|
US20050042214A1
(en)
|
2003-07-15 |
2005-02-24 |
Gershwin M. Eric |
Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
|
DK1648867T3
(da)
|
2003-07-17 |
2013-12-16 |
Plexxikon Inc |
Ppar-aktive forbindelser
|
AU2003249492A1
(en)
|
2003-07-24 |
2005-02-14 |
Eswaran Krishnan Iyer |
Oral compositions for treatment of diseases
|
WO2005012311A1
(en)
|
2003-07-31 |
2005-02-10 |
Wyeth |
N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands
|
EP1653969A4
(en)
|
2003-08-07 |
2006-12-20 |
Japan Tobacco Inc |
PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
|
WO2005018436A2
(en)
|
2003-08-26 |
2005-03-03 |
The Trustees Of Boston University |
Methods for the diagnosis, prognosis and treatment of metabolic syndrome
|
EP1664304A1
(en)
|
2003-09-22 |
2006-06-07 |
BioSpecific GmbH & Co.KG. |
Method for neutralizing effects of secreted pla2 iia
|
IL158600A
(en)
|
2003-10-26 |
2015-07-30 |
Hermona Soreq |
Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
|
JP4916886B2
(ja)
|
2003-11-12 |
2012-04-18 |
イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー |
油性植物および酵母中の多価不飽和脂肪酸レベルを変更するのに適したδ15デサチュラーゼ
|
ITMI20032247A1
(it)
|
2003-11-19 |
2005-05-20 |
Tiberio Bruzzese |
Interazione di derivati polari di composti insaturi con substrati inorganici
|
SE0303513D0
(sv)
|
2003-12-19 |
2003-12-19 |
Pronova Biocare As |
Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
|
GB2409644B
(en)
|
2003-12-31 |
2005-12-21 |
Igennus Ltd |
Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
|
IL159729A0
(en)
|
2004-01-06 |
2004-06-20 |
Doron I Friedman |
Non-aqueous composition for oral delivery of insoluble bioactive agents
|
GB0403247D0
(en)
|
2004-02-13 |
2004-03-17 |
Tillotts Pharma Ag |
A pharmaceutical composition
|
US7022713B2
(en)
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
EP1591114A1
(en)
|
2004-03-12 |
2005-11-02 |
Fournier Laboratories Ireland Limited |
Use of metformin and orlistat for the treatment or prevention of obesity
|
US20050215640A1
(en)
|
2004-03-26 |
2005-09-29 |
Baxter Jeffrey H |
HMB compositions and uses thereof
|
US7923043B2
(en)
|
2004-03-30 |
2011-04-12 |
Theta Biomedical Consulting & Development Co., Inc. |
Method for protecting humans against superficial vasodilator flush syndrome
|
US20050244367A1
(en)
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
US20050272095A1
(en)
|
2004-05-19 |
2005-12-08 |
Ppd Biomarker Discovery Sciences, Llc |
Methods of identifying biomarkers
|
US20050267145A1
(en)
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
TW200613009A
(en)
|
2004-06-11 |
2006-05-01 |
Ono Pharmaceutical Co |
Capsule having chewing stability
|
GB0413729D0
(en)
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
GB0413730D0
(en)
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
WO2006008088A2
(en)
|
2004-07-16 |
2006-01-26 |
I.N.S.E.R.M. (Institut National De La Sante Et De La Recherche Medicale) |
Secretory phospholipase a2 (spla2) as prognostic and diagnostic marker for cardiovascular diseases
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
MX2007001155A
(es)
|
2004-07-29 |
2007-08-14 |
Creabilis Therapeutics Spa |
Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
|
US20070231345A1
(en)
|
2004-08-02 |
2007-10-04 |
Muhammed Majeed |
Medicament containing natural leucotriene inhibitors singly or in combination with bioavailable organic selenium supplement for hyperproliferative dermatological conditions and therapeutic methods thereof
|
ITRM20040395A1
(it)
|
2004-08-03 |
2004-11-03 |
Sigma Tau Ind Farmaceuti |
Composizione comprendente statine e acidi grassi omega 3.
|
WO2007130714A1
(en)
|
2006-02-01 |
2007-11-15 |
Transform Pharmaceuticals, Inc. |
Novel statin pharmaceutical compositions and related methods of treatment
|
MX2007001553A
(es)
*
|
2004-08-06 |
2008-03-07 |
Transform Pharmaceuticals Inc |
Nuevas composiciones farmaceuticas de estatina y metodos de tratamiento relacionados.
|
WO2007130713A1
(en)
|
2006-02-01 |
2007-11-15 |
Transform Pharmaceuticals, Inc. |
Novel fenofibrate formulations and related methods of treatment
|
WO2006017627A2
(en)
|
2004-08-06 |
2006-02-16 |
Barry Sears |
Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
|
US20090042979A1
(en)
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
RU2382642C2
(ru)
*
|
2004-08-06 |
2010-02-27 |
Трансформ Фармасьютикалз, Инк. |
Новые фармацевтические композиции статина и связанные с ними способы лечения
|
JP4943849B2
(ja)
|
2004-08-18 |
2012-05-30 |
持田製薬株式会社 |
ゼリー組成物
|
EP2404605B1
(en)
|
2004-08-25 |
2015-04-22 |
Essentialis, Inc. |
Pharmaceutical formulations of potassium ATP channel openers and uses thereof
|
WO2006022291A1
(ja)
|
2004-08-27 |
2006-03-02 |
Senju Pharmaceutical Co, .Ltd. |
ドライアイ治療用点眼液
|
KR100545304B1
(ko)
|
2004-09-01 |
2006-05-08 |
주식회사 유니젠 |
아선약을 포함하는 운카리아 속 식물, 또는 이의 황금및/또는 녹차의 배합물을 포함하는 사이클로옥시게나제및/또는 5-리폭시게나제 억제용 조성물
|
WO2006027776A1
(en)
|
2004-09-07 |
2006-03-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
|
CN1759834B
(zh)
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
|
US20070292523A1
(en)
|
2004-09-27 |
2007-12-20 |
Joey Moodley |
Dihydropyrimidine Formulations
|
WO2006044556A2
(en)
|
2004-10-14 |
2006-04-27 |
Galileo Pharmaceuticals, Inc. |
Dual inhibitors of lipoxygenase for treating diabetes
|
EP1833313A2
(en)
|
2004-10-15 |
2007-09-19 |
Corporation Limited Photonz |
Compositions containing high omega-3 and low saturated fatty acid levels
|
ES2255426B1
(es)
|
2004-10-19 |
2007-08-16 |
Gp Pharm, S.A. |
Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
|
KR101086037B1
(ko)
|
2004-10-27 |
2011-11-22 |
에스케이케미칼주식회사 |
호흡기질환 예방 및 치료에 유용한 산두근 추출물
|
JP2008521829A
(ja)
|
2004-11-30 |
2008-06-26 |
プレキシコン,インコーポレーテッド |
Ppar活性化合物
|
FR2878747B1
(fr)
*
|
2004-12-03 |
2007-03-30 |
Pierre Fabre Medicament Sa |
Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
|
US20070191467A1
(en)
*
|
2004-12-06 |
2007-08-16 |
Reliant Pharmaceutical, Inc. |
Statin and omega-3 fatty acids for lipid therapy
|
CN101098690A
(zh)
|
2004-12-06 |
2008-01-02 |
瑞莱恩特医药品有限公司 |
用于血脂治疗的ω-3脂肪酸和脂血异常剂
|
US20090239927A1
(en)
|
2004-12-06 |
2009-09-24 |
George Bobotas |
Statin and Omega-3 Fatty Acids For Lipid Therapy
|
BRPI0518398A2
(pt)
|
2004-12-06 |
2008-11-18 |
Reliant Pharmaceuticals Inc |
Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos
|
US20060135610A1
(en)
|
2004-12-22 |
2006-06-22 |
Bortz Jonathan D |
Cardiovascular compositions
|
GB2421909A
(en)
|
2004-12-23 |
2006-07-12 |
Laxdale Ltd |
Pharmaceutical compositions comprising EPA and methods of use
|
US20080200707A1
(en)
|
2005-01-04 |
2008-08-21 |
Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. |
Lipotoxicity Relieving Agent
|
EP1834639B8
(en)
|
2005-01-04 |
2016-12-07 |
Mochida Pharmaceutical Co., Ltd. |
Remedial agent for fat toxicity
|
EP1853266B1
(en)
|
2005-01-10 |
2011-10-12 |
Cortendo AB (publ) |
2s,4r ketoconazole for treating diabetes, metabolic syndrome and other conditions
|
US20060172012A1
(en)
|
2005-01-28 |
2006-08-03 |
Finley John W |
Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
|
US20060189682A1
(en)
|
2005-02-02 |
2006-08-24 |
Payne Joseph E |
Water soluble prodrugs of COX-2 inhibitors
|
US20060235009A1
(en)
|
2005-02-08 |
2006-10-19 |
Richard Glickman |
Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
|
CA2598273A1
(en)
|
2005-02-17 |
2006-08-24 |
Merck & Co., Inc. |
Method of treating atherosclerosis, dyslipidemias and related conditions
|
US20100254951A1
(en)
|
2005-02-22 |
2010-10-07 |
Mochida Pharmaceutical Co., Ltd. |
Nerve Regeneration Promoting Agent
|
KR20070108945A
(ko)
|
2005-03-08 |
2007-11-13 |
릴라이언트 파마슈티컬스 인코퍼레이티드 |
스타틴과 오메가-3 지방산 및 그 조합물을 이용한 치료
|
CA2605510C
(en)
|
2005-04-19 |
2013-12-24 |
Surface Logix, Inc. |
Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
|
CN102050720B
(zh)
|
2005-05-04 |
2013-03-13 |
普罗诺瓦生物医药挪威公司 |
新的dha衍生物及其作为药物的用途
|
JP2008542255A
(ja)
|
2005-05-27 |
2008-11-27 |
ファイザー・プロダクツ・インク |
肥満症の治療または体重減量の維持のためのカンナビノイド−1受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
|
EP1893583B1
(en)
|
2005-05-31 |
2012-04-04 |
Pfizer Inc. |
Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
|
JP5134916B2
(ja)
|
2005-07-08 |
2013-01-30 |
持田製薬株式会社 |
心血管イベント発症予防用組成物
|
CA2570763C
(en)
*
|
2005-07-08 |
2011-08-23 |
Mochida Pharmaceutical Co., Ltd. |
Composition for preventing onset of cardiovascular events
|
WO2007011886A2
(en)
|
2005-07-18 |
2007-01-25 |
Reliant Pharmaceuticals, Inc. |
Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
|
US7628027B2
(en)
|
2005-07-19 |
2009-12-08 |
Hussmann Corporation |
Refrigeration system with mechanical subcooling
|
US20090054519A1
(en)
|
2005-07-22 |
2009-02-26 |
Abhijit Ray |
Derivatives of monosaccharides as 5-lipoxygenase inhibitors
|
RU2290185C1
(ru)
|
2005-07-26 |
2006-12-27 |
Дмитрий Николаевич Мясников |
Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
|
BRPI0614417A2
(pt)
|
2005-07-28 |
2011-03-29 |
Reliant Pharmaceuticals Inc |
composições farmacêuticas compreendendo bloqueadores de canais de cálcio de dihidropiridina e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas
|
ITMI20051560A1
(it)
|
2005-08-10 |
2007-02-11 |
Tiberio Bruzzese |
Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
|
CA2619608C
(en)
|
2005-08-18 |
2016-02-02 |
Accelalox, Inc. |
Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
|
KR100704009B1
(ko)
|
2005-08-30 |
2007-04-04 |
한국화학연구원 |
염증억제 활성을 가지는6-알킬아미노-2-메틸-2'-(n-메틸치환술폰아미도)메틸-2h-1-벤조피란 유도체
|
RU2302248C2
(ru)
|
2005-08-30 |
2007-07-10 |
Федеральное государственное унитарное предприятие Тихоокеанский научно-исследовательский рыбохозяйственный центр |
Средство, обладающее липидкорригирующими, гипокоагуляционными и антиоксидантными свойствами
|
US7405302B2
(en)
|
2005-10-11 |
2008-07-29 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
CA2626422A1
(en)
|
2005-10-18 |
2007-04-26 |
Aegerion Pharmaceuticals |
Methods for treating disorders associated with hyperlipidemia in a mammal
|
US20070093524A1
(en)
|
2005-10-25 |
2007-04-26 |
Wyeth |
5-Lipoxygenase modulators
|
WO2007051065A2
(en)
|
2005-10-28 |
2007-05-03 |
Numerate, Inc. |
Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
|
US7977359B2
(en)
|
2005-11-04 |
2011-07-12 |
Amira Pharmaceuticals, Inc. |
5-lipdxygenase-activating protein (FLAP) inhibitors
|
US20070219206A1
(en)
|
2005-11-04 |
2007-09-20 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
US20070105793A1
(en)
|
2005-11-04 |
2007-05-10 |
Curt Hendrix |
Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
|
US20070225285A1
(en)
|
2005-11-04 |
2007-09-27 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
US20070244128A1
(en)
|
2005-11-04 |
2007-10-18 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
GB2431927B
(en)
|
2005-11-04 |
2010-03-17 |
Amira Pharmaceuticals Inc |
5-Lipoxygenase-activating protein (FLAP) inhibitors
|
US20070104779A1
(en)
|
2005-11-07 |
2007-05-10 |
Rongen Roelof M |
Treatment with omega-3 fatty acids and products thereof
|
EP1946755B1
(en)
*
|
2005-11-11 |
2017-03-15 |
Mochida Pharmaceutical Co., Ltd. |
Jelly composition
|
WO2007059515A2
(en)
|
2005-11-15 |
2007-05-24 |
Baxter International, Inc. |
Compositions of lipoxygenase inhibitors
|
WO2007058523A1
(en)
|
2005-11-17 |
2007-05-24 |
N.V. Nutricia |
Composition with docosapentaenoic acid
|
BRPI0520669A2
(pt)
|
2005-11-21 |
2009-06-02 |
Teva Pharma |
dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
|
US20070202206A1
(en)
|
2005-11-29 |
2007-08-30 |
Palu Afa K |
Morinda Citrifolia Leaf Juice And Leaf Extract Based Formulations
|
MX286464B
(es)
|
2005-12-20 |
2011-05-10 |
Cenestra Llc |
Formulaciones de acido graso omega 3.
|
US20070237848A1
(en)
|
2005-12-21 |
2007-10-11 |
Brad Rawson |
MORINDA CITRIFOLIA BASED COMPOSITIONS FOR TREATMENT OF ANTI-INFLAMMATORY DISEASES THROUGH INHIBITION OF COX-1, COX-2, INTERLEUKIN-1beta, INTERLEUKIN-6, TNF-alpha, HLE, AND iNOS
|
EP1800675B1
(en)
|
2005-12-23 |
2011-05-18 |
N.V. Nutricia |
Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
|
WO2007081773A2
(en)
|
2006-01-05 |
2007-07-19 |
Reliant Pharmaceuticals, Inc |
Treatment of fatty liver
|
CA2636043A1
(en)
|
2006-01-23 |
2007-08-02 |
Amira Pharmaceuticals, Inc. |
Tricyclic inhibitors of 5-lipoxygenase
|
US20070202159A1
(en)
|
2006-02-02 |
2007-08-30 |
Mathur Rajeev S |
Pharmaceutical composition comprising stabilized statin particles
|
ES2448424T3
(es)
*
|
2006-02-07 |
2014-03-13 |
Mochida Pharmaceutical Co., Ltd. |
Composición para prevenir la recurrencia de accidente cerebrovascular
|
JP4005104B2
(ja)
|
2006-02-07 |
2007-11-07 |
持田製薬株式会社 |
脳卒中再発予防用組成物
|
JP5069448B2
(ja)
|
2006-02-07 |
2012-11-07 |
持田製薬株式会社 |
脳卒中再発予防用組成物
|
AU2007215207A1
(en)
|
2006-02-14 |
2007-08-23 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
|
CA2642216A1
(en)
|
2006-02-21 |
2007-08-30 |
Critical Therapeutics, Inc. |
New crystal forms and pharmaceutical compositions of (+)-r-zileuton
|
CN101437508A
(zh)
|
2006-03-03 |
2009-05-20 |
孟山都技术有限公司 |
用于改善心血管健康的十八碳四烯酸
|
EP2081550B2
(en)
|
2006-03-09 |
2021-05-26 |
Reliant Pharmaceuticals, Inc. |
Coating capsules with active pharmaceutical ingredients
|
US8784886B2
(en)
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
WO2007128801A1
(en)
|
2006-05-08 |
2007-11-15 |
Novartis Ag |
Combination of organic compounds
|
EP2777701A1
(en)
|
2006-05-31 |
2014-09-17 |
Mochida Pharmaceutical Co., Ltd. |
Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid
|
US20090042835A1
(en)
|
2006-06-02 |
2009-02-12 |
Davis Roger A |
Compositions and methods for ameliorating hyperlipidemia
|
WO2007143164A1
(en)
|
2006-06-02 |
2007-12-13 |
San Diego State University Research Foundation |
Compositions and methods for ameliorating hyperlipidemia
|
US20070292501A1
(en)
|
2006-06-05 |
2007-12-20 |
Udell Ronald G |
Chewable soft gelatin capsules
|
JP5658876B2
(ja)
|
2006-07-05 |
2015-01-28 |
フォトンズ コーポレーション リミテッド |
大規模従属栄養培養領域にて産生される超高純度epaと極性脂質
|
US20090304784A1
(en)
|
2006-07-28 |
2009-12-10 |
V. Mane Fils |
Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
|
JP5223177B2
(ja)
|
2006-08-23 |
2013-06-26 |
地方独立行政法人北海道立総合研究機構 |
アルミニウム回収用材料、同材料の製造方法及びアルミニウムの回収方法
|
CA2661404A1
(en)
|
2006-09-05 |
2008-03-13 |
Schering Corporation |
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
|
US20080085911A1
(en)
|
2006-10-10 |
2008-04-10 |
Reliant Pharmaceuticals, Inc. |
Statin and omega-3 fatty acids for reduction of apo-b levels
|
CN101553221A
(zh)
|
2006-10-10 |
2009-10-07 |
瑞莱恩特医药品有限公司 |
用于降低APO-B水平的抑制素和ω-3脂肪酸
|
WO2008063323A2
(en)
*
|
2006-10-13 |
2008-05-29 |
Reliant Pharmaceuticals, Inc. |
Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
|
WO2008088415A1
(en)
|
2006-10-18 |
2008-07-24 |
Reliant Pharmaceuticals, Inc. |
Omega-3 fatty acids for reduction of lp-pla2 levels
|
US20080306154A1
(en)
*
|
2006-11-03 |
2008-12-11 |
My Svensson |
Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
|
US20080125490A1
(en)
*
|
2006-11-03 |
2008-05-29 |
My Svensson |
Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
|
US20080226758A1
(en)
|
2006-11-28 |
2008-09-18 |
Shixin Deng |
Lipoxygenase and Cyclooxygenase Inhibition
|
US20090042849A1
(en)
|
2006-12-06 |
2009-02-12 |
Yochai Birnbaum |
Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
|
AU2007338625A1
(en)
|
2006-12-21 |
2008-07-03 |
Aegerion Pharmaceuticals, Inc. |
Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
|
ES2524320T3
(es)
|
2007-01-17 |
2014-12-05 |
Mochida Pharmaceutical Co., Ltd. |
Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
|
EP2120959A4
(en)
|
2007-01-23 |
2010-05-26 |
Reddys Lab Ltd Dr |
METHOD AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES AND DIABETES-BASED DYSLIPIDEMIA
|
US20080185198A1
(en)
|
2007-02-02 |
2008-08-07 |
Steven Mark Jones |
Next generation hybrid III parallel/series hybrid system
|
WO2008100423A1
(en)
|
2007-02-09 |
2008-08-21 |
Sirtris Pharmaceuticals, Inc. |
Gut microsomal triglyceride transport protein inhibitors
|
DK2121576T3
(en)
|
2007-02-15 |
2016-02-15 |
Ct De Rech Sur Les Biotechnologies Marine |
Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
|
WO2008106787A1
(en)
|
2007-03-06 |
2008-09-12 |
Bioriginal Food & Science Corporation |
Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
|
WO2008115529A1
(en)
|
2007-03-20 |
2008-09-25 |
Reliant Pharmaceuticals, Inc. |
Compositions comprising omega-3 fatty acids and cetp inhibitors
|
US8048880B2
(en)
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
WO2008145170A1
(de)
|
2007-05-31 |
2008-12-04 |
Siemens Aktiengesellschaft |
Verfahren zum konfigurieren einer automatisierungsanlage
|
US20080299187A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Joar Opheim |
Substances for Reducing Occurence of Major Cardiac Events in Humans
|
TW200914437A
(en)
|
2007-06-20 |
2009-04-01 |
Ironwood Pharmaceuticals Inc |
FAAH inhibitors
|
US20100119598A1
(en)
|
2007-06-29 |
2010-05-13 |
Takeda Pharmaceutical Company Limited |
Seamless capsule
|
US20090092595A1
(en)
|
2007-07-13 |
2009-04-09 |
Regents Of The University Of California |
Suppression of sPLA2-integrin binding for treating an inflammatory condition
|
US20090062369A1
(en)
|
2007-08-31 |
2009-03-05 |
Joaquim Trias |
Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
|
EP2205231A1
(en)
|
2007-10-01 |
2010-07-14 |
NeuroSearch A/S |
Pharmaceutical compositions of 5-hydr0xytrypt0phan and serotonin-enhancing compound
|
US8361534B2
(en)
|
2007-12-20 |
2013-01-29 |
Abbott Laboratories |
Stable nutritional powder
|
WO2009085388A2
(en)
|
2007-12-20 |
2009-07-09 |
Abbott Laboratories |
Stable nutritional powder
|
EA201070835A1
(ru)
|
2008-01-10 |
2011-02-28 |
Такеда Фармасьютикал Компани Лимитед |
Состав капсулы
|
US20090182049A1
(en)
|
2008-01-16 |
2009-07-16 |
Joar Arild Opheim |
Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
|
MX2010012482A
(es)
|
2008-05-15 |
2010-12-01 |
Pronova Biopharma Norge As |
Proceso para aceite de kril.
|
US20110118350A1
(en)
|
2008-05-20 |
2011-05-19 |
Mochida Pharmaceutical Co., Ltd. |
Composition for preventing cardiovascular event in high-risk patient
|
JPWO2009151125A1
(ja)
|
2008-06-13 |
2011-11-17 |
持田製薬株式会社 |
肝障害の診断及び治療
|
WO2009151116A1
(ja)
|
2008-06-13 |
2009-12-17 |
持田製薬株式会社 |
非アルコール性脂肪肝炎の予防/改善・治療薬
|
JPWO2009154230A1
(ja)
|
2008-06-17 |
2011-12-01 |
持田製薬株式会社 |
非アルコール性脂肪肝炎の予防/改善・治療薬
|
WO2010004982A1
(ja)
|
2008-07-07 |
2010-01-14 |
持田製薬株式会社 |
脂質異常症の改善または治療薬
|
ES2862336T3
(es)
|
2008-09-02 |
2021-10-07 |
Amarin Pharmaceuticals Ie Ltd |
Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
|
EP2343066A4
(en)
|
2008-09-30 |
2012-08-29 |
Mochida Pharm Co Ltd |
THERAPEUTIC AGENT FOR HEPATITIS C
|
US20100130608A1
(en)
|
2008-10-01 |
2010-05-27 |
Martek Biosciences Corporation |
Compositions and methods for reducing triglyceride levels
|
US20120035105A1
(en)
|
2009-01-09 |
2012-02-09 |
Sdg, Inc. |
Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
|
WO2010083615A1
(en)
|
2009-01-26 |
2010-07-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein c-iii expression
|
LT2596786T
(lt)
|
2009-02-10 |
2020-01-10 |
Amarin Pharmaceuticals Ireland Limited |
Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti
|
KR101841756B1
(ko)
|
2009-03-09 |
2018-03-23 |
프로노바 바이오파마 너지 에이에스 |
지방산 오일 혼합물 및 계면활성제를 포함하는 조성물 및 이의 방법 및 사용
|
US8241672B2
(en)
|
2009-03-11 |
2012-08-14 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
WO2010117951A1
(en)
|
2009-04-06 |
2010-10-14 |
The Regents Of The University Of California |
Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
|
DK3278665T3
(da)
|
2009-04-29 |
2020-11-30 |
Amarin Pharmaceuticals Ie Ltd |
Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
|
NZ771180A
(en)
|
2009-04-29 |
2022-07-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
US8618168B2
(en)
|
2009-05-22 |
2013-12-31 |
Mochida Pharmaceutical Co., Ltd. |
Self-emulsifying composition of OMEGA3 fatty acid
|
CN102625847A
(zh)
|
2009-06-15 |
2012-08-01 |
阿马里纳制药公司 |
在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
|
RU2402326C1
(ru)
|
2009-06-22 |
2010-10-27 |
Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) |
Способ коррекции инсулинорезистентности при метаболическом синдроме
|
US8557275B2
(en)
|
2009-07-23 |
2013-10-15 |
U.S. Nutraceuticals, LLC |
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
|
CN102724877B
(zh)
|
2009-09-01 |
2015-05-13 |
凯特贝希制药公司 |
脂肪酸烟酸缀合物及其用途
|
MX2012003555A
(es)
|
2009-09-23 |
2012-07-03 |
Amarin Corp Plc |
Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
|
ES2661812T3
(es)
|
2009-10-16 |
2018-04-04 |
Mochida Pharmaceutical Co., Ltd. |
Composiciones
|
US9060981B2
(en)
|
2009-10-16 |
2015-06-23 |
Mochida Pharmaceutical Co., Ltd. |
Marker associated with non-alcoholic steatohepatitis
|
JP5771627B2
(ja)
|
2010-01-08 |
2015-09-02 |
カタバシス ファーマシューティカルズ,インコーポレイテッド |
脂肪酸フマル酸塩誘導体およびそれらの使用
|
WO2011087981A2
(en)
|
2010-01-15 |
2011-07-21 |
E. I. Du Pont De Nemours And Company |
Clinical benefits of eicosapentaenoic acid in humans
|
EP3583849A1
(en)
|
2010-03-04 |
2019-12-25 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating and/or preventing cardiovascular disease
|
US8846321B2
(en)
|
2010-03-12 |
2014-09-30 |
President And Fellows Of Harvard College |
Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
|
US8663704B2
(en)
|
2010-04-30 |
2014-03-04 |
U.S. Nutraceuticals, LLC |
Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
|
GB2480146A
(en)
|
2010-05-05 |
2011-11-09 |
St Giles Foods Ltd |
Fruit or vegetable based edible composition comprising nutritional supplement
|
US8609138B2
(en)
|
2010-06-30 |
2013-12-17 |
Mochida Pharmaceutical Co., Ltd. |
ω3 fatty acid compound preparation
|
WO2012032414A2
(en)
|
2010-09-08 |
2012-03-15 |
Pronova Biopharma Norge As |
Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
|
US10557856B2
(en)
|
2010-09-24 |
2020-02-11 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Biomarkers of renal injury
|
CA2815361A1
(en)
|
2010-10-20 |
2012-04-26 |
Glycomark, Inc. |
Improved identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
|
CN104814950A
(zh)
|
2010-11-09 |
2015-08-05 |
持田制药株式会社 |
血糖值上升抑制剂在制造经口摄取用食品中的应用
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
AU2011336856A1
(en)
|
2010-11-29 |
2013-07-04 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
EP2471537A1
(en)
|
2010-12-30 |
2012-07-04 |
PregLem S.A. |
Treatment of pain associated with dislocation of basal endometrium
|
EP2502506A1
(en)
|
2011-03-21 |
2012-09-26 |
Abbott Laboratories |
Methods for improving bone health in infants using long chain polyunsaturated fatty acids
|
KR101310710B1
(ko)
|
2011-03-23 |
2013-09-27 |
한미약품 주식회사 |
오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물
|
US20120264824A1
(en)
|
2011-04-15 |
2012-10-18 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US8660662B2
(en)
|
2011-04-22 |
2014-02-25 |
Medtronic, Inc. |
Low impedance, low modulus wire configurations for a medical device
|
KR20190062511A
(ko)
|
2011-04-27 |
2019-06-05 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지방단백질 ciii (apociii) 발현의 조정
|
CN103957903A
(zh)
|
2011-09-15 |
2014-07-30 |
翁特拉制药公司 |
用于治疗、逆转、抑制或预防对抗血小板治疗的耐受性的方法和组合物
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
EP2792746A4
(en)
|
2011-12-12 |
2015-09-16 |
Nat Cerebral & Cardiovascular Ct |
OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE
|
WO2013103958A1
(en)
|
2012-01-06 |
2013-07-11 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
|
WO2013136277A1
(en)
|
2012-03-13 |
2013-09-19 |
Unimark Remedies Ltd. |
Pharmaceutical compositions for treatment of cardiovascular diseases
|
EP2830602B1
(en)
|
2012-03-30 |
2020-10-21 |
Micelle BioPharma, Inc. |
Omega-3 fatty acid ester compositions
|
RU2645075C2
(ru)
|
2012-05-07 |
2018-02-15 |
Омтера Фармасьютикалс, Инк. |
Композиции статинов и омега-3 жирных кислот
|
ES2749201T3
(es)
|
2012-05-15 |
2020-03-19 |
Mochida Pharm Co Ltd |
Agente de prevención primaria de enfermedad cardiovascular para pacientes que tienen altos niveles en sangre de proteína C reactiva de alta sensibilidad
|
CN104540551A
(zh)
|
2012-05-30 |
2015-04-22 |
科莱恩金融(Bvi)有限公司 |
包含氨基酸表面活性剂、甜菜碱和n-甲基-n-酰基葡糖胺的具有更好的泡沫质量和更高粘度的组合物
|
US20130324607A1
(en)
|
2012-06-05 |
2013-12-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypercholesterolemia
|
US20140080850A1
(en)
|
2012-06-05 |
2014-03-20 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
|
CA2876139A1
(en)
|
2012-06-07 |
2013-12-12 |
President And Fellows Of Harvard College |
Nanotherapeutics for drug targeting
|
CA2916208A1
(en)
|
2012-06-17 |
2013-12-27 |
Matinas Biopharma, Inc. |
Omega-3 pentaenoic acid compositions and methods of use
|
CN104837487A
(zh)
|
2012-06-29 |
2015-08-12 |
阿玛林制药爱尔兰有限公司 |
治疗儿童代谢综合征的方法
|
US20140005265A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods for treating hypertriglyceridemia
|
US20140004183A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods for treating cardiovascular disease in statin-tolerant subjects
|
HUE053111T2
(hu)
|
2012-06-29 |
2021-06-28 |
Amarin Pharmaceuticals Ie Ltd |
Módszerek kardiovaszkuláris események veszélyének csökkentésére sztatin terápiával kezelt alanyban eikozapentaénsav-etilészter alkalmazásával
|
US20150157593A1
(en)
|
2012-06-29 |
2015-06-11 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing ldl-p
|
EP2902020A4
(en)
|
2012-09-28 |
2016-03-23 |
Mochida Pharm Co Ltd |
COMPOSITION FOR REDUCING NEW DIABETES APPARITIONS
|
EP2719382A1
(en)
|
2012-10-12 |
2014-04-16 |
Mochida Pharmaceutical Co., Ltd. |
Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis
|
US9486433B2
(en)
|
2012-10-12 |
2016-11-08 |
Mochida Pharmaceuticals Co. Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US20140142127A1
(en)
|
2012-10-23 |
2014-05-22 |
Almburg, Llc |
Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
US8703188B1
(en)
*
|
2012-11-19 |
2014-04-22 |
Azanta A/S |
Dispersible tablet
|
US20140213648A1
(en)
|
2012-12-31 |
2014-07-31 |
Amarin Pharmaceuticals Ireland Limited |
Methods of increasing epa blood levels
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US20140221676A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating and/or preventing cardiovascular disease
|
US20140221452A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
|
US20140221358A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US20140242216A1
(en)
|
2013-02-24 |
2014-08-28 |
Mead Johnson Nutrition Company |
Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System
|
US20140249200A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
|
US20140249220A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
|
US20140249214A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of warfarin and ethyl eicosapentaenoate
|
US20140249225A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
US20140255537A1
(en)
|
2013-03-11 |
2014-09-11 |
Mead Johnson Nutrition Company |
Nutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof
|
US9661874B2
(en)
|
2013-03-11 |
2017-05-30 |
Mead Johnson Nutrition Company |
Nutritional compositions containing structured fat globules and uses thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271907A1
(en)
|
2013-03-14 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
|
US20140275252A1
(en)
|
2013-03-14 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating traumatic brain injury
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
AU2014230444B2
(en)
|
2013-03-15 |
2018-05-17 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US10441560B2
(en)
|
2013-03-15 |
2019-10-15 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
WO2014179325A1
(en)
|
2013-04-29 |
2014-11-06 |
Matinas Biopharma, Inc. |
Omega-3 fatty acid formulations for use as pharmaceutical treatment
|
KR102240429B1
(ko)
|
2013-05-06 |
2021-04-15 |
한미약품 주식회사 |
로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
|
US20140357717A1
(en)
|
2013-06-04 |
2014-12-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
BR112015030203A2
(pt)
|
2013-06-07 |
2017-07-25 |
The California Institute For Biomedical Res |
moléculas pequenas inibidores da fibrose
|
US20160135702A1
(en)
|
2013-06-21 |
2016-05-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Techniques for Predicting Cardiac Arrhythmias Based on Signals from Leads of Electrocardiography
|
CN111939125A
(zh)
|
2013-07-18 |
2020-11-17 |
持田制药株式会社 |
ω-3脂肪酸的自乳化组合物
|
EP3023098B1
(en)
|
2013-07-18 |
2020-06-24 |
Mochida Pharmaceutical Co., Ltd. |
Self-emulsifying composition of omega-3 fatty acid
|
WO2015021141A1
(en)
|
2013-08-06 |
2015-02-12 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
|
US20150051282A1
(en)
|
2013-08-14 |
2015-02-19 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US20150073050A1
(en)
|
2013-09-09 |
2015-03-12 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
|
WO2015053379A1
(en)
|
2013-10-07 |
2015-04-16 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
WO2015066512A1
(en)
|
2013-10-31 |
2015-05-07 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
KR102374499B1
(ko)
|
2014-04-11 |
2022-03-14 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
Nafld 및 nash 의 치료
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
CA2955373A1
(en)
|
2014-08-01 |
2016-02-04 |
Western Michigan University Research Foundation |
Self-supported electronic devices
|
MY185428A
(en)
|
2015-01-21 |
2021-05-19 |
Mochida Pharm Co Ltd |
Self-emulsifying composition of ?-3 fatty acid
|
US20180015038A1
(en)
|
2015-01-21 |
2018-01-18 |
Mochida Pharmaceutical Co., Ltd. |
Omega-3 fatty acid self-emulsifying composition
|
WO2016140949A1
(en)
|
2015-03-02 |
2016-09-09 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
US20170151202A1
(en)
|
2015-09-09 |
2017-06-01 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
SI3275438T1
(sl)
|
2016-07-29 |
2021-05-31 |
Kowa Company, Ltd. |
Metode preprečevanja kardiovaskularnih dogodkov pri dislipidemični populaciji z rezidualnim tveganjem
|
US11197870B2
(en)
|
2016-11-10 |
2021-12-14 |
Galmed Research And Development Ltd |
Treatment for hepatic fibrosis
|
TW201900160A
(zh)
|
2017-05-19 |
2019-01-01 |
愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 |
用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
|
US20190054054A1
(en)
|
2017-08-15 |
2019-02-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods reducing or preventing oxidation of high density lipoprotein (HDL)
|
US20190054058A1
(en)
|
2017-08-15 |
2019-02-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods of Treating or Preventing Bone Loss
|
US20190209506A1
(en)
|
2018-01-09 |
2019-07-11 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
US20190275057A1
(en)
|
2018-03-06 |
2019-09-12 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus
|
SG11202101562UA
(en)
|
2018-08-17 |
2021-03-30 |
Amarin Pharmaceuticals Ie Ltd |
Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
|
FI4056176T3
(fi)
|
2018-09-24 |
2024-05-30 |
Amarin Pharmaceuticals Ie Ltd |
Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa
|
BR112021005813A2
(pt)
|
2018-09-26 |
2021-06-29 |
Amarin Pharmaceuticals Ireland Limited |
composições e métodos para tratar ou prevenir doenças e/ou distúrbios causados pela exposição à poluição do ar
|
WO2020168251A1
(en)
|
2019-02-15 |
2020-08-20 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of a cardiovascular event in a statin-treated subject by increasing serum and plasma epa and dpa levels
|
US20220265749A1
(en)
|
2019-08-01 |
2022-08-25 |
Evonik Operations Gmbh |
Preparation comprising omega-3 fatty acid salts and extracts of gum resins from boswellia species
|
JP2022554020A
(ja)
|
2019-11-12 |
2022-12-27 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
心房細動および/または心房粗動を患う対象における心血管イベントのリスクを低減する方法
|